cyclosporine has been researched along with Neoplasms in 260 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 100 (38.46) | 18.2507 |
| 2000's | 93 (35.77) | 29.6817 |
| 2010's | 59 (22.69) | 24.3611 |
| 2020's | 8 (3.08) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Chow, LM; Duan, LX; Hu, X; Jiang, T; Li, XM; Liu, T; Liu, Z; Wan, SB; Wang, BC; Wong, IL; Yuan, J; Zhang, XY | 1 |
| Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L | 1 |
| Spindler, A; Stefan, K; Wiese, M | 1 |
| Kmoníčková, E; Peterková, L; Rimpelová, S; Ruml, T | 1 |
| Aichholz, R; Beltz, K; Bigaud, M; Blatter, M; Bornancin, F; Calzascia, T; Endres, R; Erbel, P; Kieffer, L; Mcsheehy, P; Melkko, S; Pissot Soldermann, C; Quancard, J; Radimerski, T; Régnier, CH; Renatus, M; Schlapbach, A; Simic, O; Sorge, M; Wagner, T; Wartmann, M; Weiss, A | 1 |
| Chang, YT; Chou, YJ; Pan, TY; Wu, CY | 1 |
| Kim, HS; Lee, JS; Park, JH; Sharma, S; Shin, JK; Yoon, S | 1 |
| Chen, M; Chen, Y; Han, B; Wan, Z; Zhang, S; Zhuang, J | 1 |
| Amini, A; Mesbah, G; Safdari, Y; Tash Shamsabadi, F; Zeyghami, MA | 1 |
| Acharya, NR; Artornsombudh, P; Begum, HA; Bhatt, NP; Buchanich, JM; Daniel, E; Dreger, KA; Dunn, JP; Fitzgerald, TD; Foster, CS; Gangaputra, SS; Goldstein, DA; Helzlsouer, KJ; Holland, GN; Jabs, DA; Kaçmaz, RO; Kempen, JH; Khachatryan, N; Kothari, S; Leiderman, YI; Levy-Clarke, GA; Liesegang, TL; Lowder, CY; Maghsoudlou, A; Newcomb, CW; Nussenblatt, RB; Pak, CM; Payal, AR; Pujari, SS; Read, RW; Rosenbaum, JT; Sen, HN; Sobrin, L; Suga, HK; Suhler, EB; Thorne, JE; Washington, TL | 1 |
| Chu, MY; Huang, HC; Li, EM; Xu, LY | 1 |
| Denecke, T; Eurich, D; Neuhaus, P; Neuhaus, R; Oellinger, R; Pascher, A; Pratschke, J; Rademacher, S; Schoening, W; Schott, E; Seehofer, D; Sinn, M | 1 |
| Bodeau, S; Choukroun, G; Galmiche, A; Pluquet, O; Sauzay, C | 1 |
| Dai, W; Gao, W; He, B; Lin, Z; Mei, D; Wang, D; Wang, X; Yang, X; Zhang, H; Zhang, Q | 1 |
| Boncela, J; Kryczka, J | 1 |
| Ding, S; Patel, N; Zhang, H | 1 |
| Dutz, J; Evans, M; Kirchhof, M; Miliszewski, M; Papp, A; Sikora, S; Song, D | 1 |
| Fan, LQ; Kong, JW; Mao, JH; Song, ZT; Wang, FJ; Zhang, LW; Zhao, J | 1 |
| Avery, BA; Castellano, RK; Chiang, CW; Davis, BJ; Ferreira, RB; Ghilardi, AF; Heldermon, CD; Law, BK; Law, ME; Narayan, S; Rodriguez, E; Sharma, A; Wang, M; Yaaghubi, E | 1 |
| Arranto, C; Baldomero, H; Gerull, S; Halter, JP; Heim, D; Kleber, M; Medinger, M; Passweg, JR; Soltermann, Y | 1 |
| Flores, C; Fouquet, G; Hermine, O; Maciel, TT; Moura, IC | 1 |
| Ambudkar, SV; Lusvarghi, S; Raju, N; Sajid, A; Swenson, RE; Vahedi, S | 1 |
| Kaden, J; Völp, A; Wesslau, C | 1 |
| Aydin, F; Canturk, T; Senturk, N; Turanli, AY; Yuksel, EP | 1 |
| Angele, MK; Bruns, C; Graeb, C; Guba, M; Jauch, KW; Khandoga, A; Pratschke, S; Rentsch, M; Schwarz, B; Wimmer, CD | 1 |
| Hsiao, FY; Hsu, WW | 1 |
| Eisenberg, S | 1 |
| Hamilton, G | 1 |
| Barle, EL; Bechter, R; Kuster, M; Perino, C; Probst, A; Thielen, S; Ulrich, P; Winkler, GC | 1 |
| Bernard, E; Bleyzac, N; Dony, A; Garnier, N; Mialou, V; Renard, C | 1 |
| Altomare, G; Ayala, F; Bardazzi, F; Bellia, G; Chimenti, S; Colombo, D; Flori, ML; Girolomoni, G; Micali, G; Parodi, A; Peris, K; Vena, GA | 1 |
| Chang, YT; Chen, CC; Chen, DY; Chen, YJ; Ho, HJ; Kuo, KN; Liu, HN; Shen, JL; Wu, CY | 1 |
| Aronson, LR; Holmes, ES; Mariano, A; Volk, SW; Wormser, C | 1 |
| Assenat, E; Bismuth, M; Carenco, C; Chanques, G; Danan, G; Duny, Y; Faure, S; Herrero, A; Jaber, S; Larrey, D; Navarro, F; Pageaux, GP; Ursic-Bedoya, J | 1 |
| Akhavanpoor, M; Bruckner, T; Darche, FF; Doesch, AO; Ehlermann, P; Erbel, C; Frankenstein, L; Gleissner, CA; Helmschrott, M; Katus, HA; Klein, B; Rivinius, R; Ruhparwar, A; Schmack, B; Thomas, D | 1 |
| Chen, KH; Hu, RH; Lee, CY; Tsai, MK; Wu, FL; Yang, CY; Yeh, CC | 1 |
| Badoux, X; Choi, PY; Chong, BH; Ho, SJ; Ramanathan, S; Roncolato, F | 1 |
| Ata, P; Demir, T; Eriş, C; Gökçe, AM; Kara, M; Özdemir, E; Ozel, L; Titiz, MI | 1 |
| Augustin, M; Mrowietz, U; Radtke, MA; Reich, K; Rustenbach, SJ; Spehr, C; Thaci, D | 1 |
| Ariga, T; Cho, Y; Iguchi, A; Kobayashi, R; Ohshima, J; Sato, TZ; Sugiyama, M; Terashita, Y | 1 |
| Aamdal, S; Andersson, Y; Brunsvig, P; Dueland, S; Engebraaten, O; Fodstad, Ø; Juell, S | 1 |
| Diem, S; Larkin, J; Spain, L | 1 |
| Thervet, É | 1 |
| Exton, LS; Kirby, B; Mohd Mustapa, MF; Smith, CH; Warren, RB; Weatherhead, SC; Yesudian, PD | 1 |
| André, N; Boulamery, A; Coze, C; Dupouey, J; Galambrun, C; Guilhaumou, R; Marsot, A; Simon, N | 1 |
| Alberu, J; Del Carmen Rial, M; Grinyó, JM; Jones-Burton, C; Kamar, N; Manfro, RC; Nainan, G; Steinberg, SM; Vincenti, F | 1 |
| Chadban, SJ; Kanellis, J; Lim, WH; Pilmore, H; Russ, GR; Wong, G | 1 |
| Chen, JS; Chen, PM; Chu, Z; Figg, WD; Gardner, ER; Liau, CT; Lin, YC; Sparreboom, A; Wang, HM; Yang, MH | 1 |
| Gottlieb, AB; Korman, N; Krueger, GG; Sterry, W; Van De Kerkhof, P | 1 |
| Botturi, A; Bruzzone, MG; Ciceri, E; Erbetta, A; Potepan, P; Salmaggi, A; Sghirlanzoni, A; Silvani, A | 1 |
| Buell, C; Koo, J | 1 |
| Benoit, G; Cantarovich, M; Charpentier, B; Durrbach, A; Hiesse, C; Ladouceur, M | 1 |
| Alberu, J; Brennan, DC; Campistol, JM; del Carmen Rial, M; Goldberg-Alberts, R; Li, H; Neylan, JF; Oberbauer, R; Pascoe, MD; Polinsky, MS; Racusen, L; Scarola, J; Schena, FP | 1 |
| Grimes, JA; Holzman, G; McAnulty, JF; Schmiedt, CW | 1 |
| Hou, G; Kim, YS; Liu, S; Shi, J; Zhai, S | 1 |
| Gatt, ME; Kedmi, M; Levy, L; Nasereddin, A; Rav-Acha, M; Rund, D | 1 |
| Oberbauer, R | 1 |
| Cass, A; Eris, J; Gallagher, M; Jardine, M; McDonald, S; Perkovic, V; Petrie, J | 1 |
| Brüne, B; Dehne, N; Herr, B; Menrad, H; Namgaladze, D; Weigert, A; Werno, C; Zhou, J | 1 |
| Boffa, DJ; Hojo, M; Luan, FL; Maluccio, M; Suthanthiran, M | 1 |
| Böhlke, M; Henry, K; Kim, J; Maher, TJ; Sani, SN; Stricker-Krongrad, A | 1 |
| Chang, HH; Chen, IM; Chen, PL; Hsieh, YC; Lai, ST; Shih, CC; Weng, ZC; Yang, AH | 1 |
| Madoulet, C; Morjani, H | 1 |
| Arakawa, N; Gushima, Y; Honda, M; Ichikado, K; Iwamoto, N; Kawamura, K; Kuda, T; Muranaka, H; Suga, M; Takaki, M | 1 |
| Abraham, JM; Thompson, JA | 1 |
| de Man, RA; Hansen, BE; Kazemier, G; Kwekkeboom, J; Metselaar, HJ; Sint Nicolaas, J; Tha-In, T; Tilanus, HW; Tjon, AS; van der Laan, LJ | 1 |
| Malta, JB; Mian, SI; Musch, DC; Rhoades, W; Shtein, RM; Soong, HK; Sugar, A | 1 |
| Ahmed, AR; Christen, WG; Gürcan, HM; Keskin, DB; Mabrouk, D | 1 |
| Burgos, FJ; Fernández-Rodriguez, A; Galeano, C; Jiménez-Alvaro, S; Marcén, R; Quereda, C; Rivera, M; Teruel, JL | 1 |
| Bachireddy, P; Braunstein, L; Crosby, E; Fan, AC; Felsher, DW; Kopelman, A; Rakhra, K; Ryeom, S; Xu, L; Yang, Q; Zabuawala, T; Zeiser, R | 1 |
| Celik, S; Dengler, TJ; Doesch, AO; Ehlermann, P; Frankenstein, L; Katus, HA; Konstandin, M; Kristen, A; Müller, S; Sack, FU | 1 |
| Alberú, J | 1 |
| Boeckmann, L; Emmert, S; Kobayashi, N; Kuschal, C; Laspe, P; Mori, T; Oetjen, E; Schön, MP; Thoms, KM | 1 |
| Giese, T; Meuer, S; Schnitzler, P; Sommerer, C; Zeier, M | 1 |
| Bistrup, C; Marckmann, P; Sodemann, U | 1 |
| Sachar, DB | 1 |
| Cointault, O; Esposito, L; Garrouste, C; Guilbeau-Frugier, C; Guitard, J; Kamar, N; Lavayssière, L; Nogier, MB; Ribes, D; Rostaing, L | 1 |
| Kessler, CS; Khan, BA; Lai-Miller, K | 1 |
| He, WJ; Tan, NH; Xu, HM; Xu, WY; Zeng, GZ; Zhao, SM | 1 |
| Bian, XK; Hou, ZH; Jia, YF; Lu, N; Si, YQ; Zhang, Y | 1 |
| Józefowicz-Okonkwo, G; Robak, T; Szmigielska-Kapłon, A | 1 |
| Andany, MA; Kasiske, BL | 1 |
| deB Edwardes, MD; Fernandes, M; Habbab, F; Loertscher, R; Meterissian, S; Tremblay, F | 1 |
| Chagnac, A; Gafter, U; Herman, M; Korzets, A; Malachi, T; Ori, Y; Weinstein, T; Zevin, D | 3 |
| Frickhofen, N; Heimpel, H; Kaltwasser, JP; Schrezenmeier, H | 1 |
| Davidson, A; Dick, G; Pinkerton, R; Pritchard-Jones, K | 1 |
| Burke, E; Burkhoff, D; Edwards, N; Itescu, S; LaManca, J; Mancini, D; Marks, AR; Oz, M; Pinney, S | 1 |
| Bravo-Hernández, G; Estrada, E; Gómez-Rangel, D; López-Martínez, B; Manuel Hernández, J; Marín-López, A; Ruiz-Argüelles, GJ | 1 |
| Hídvégi, M; Járay, J; Langer, RM; Perner, F; Tóth, A; Végsö, G | 1 |
| Bakker, RC; Bruijn, JA; de Fijter, JW; Hollander, AA; Mallat, MJ; Paul, LC | 1 |
| Ackerstein, A; Bitan, M; Elad, S; Miron, S; Or, R; Resnick, IB; Samuel, S; Shapira, MY; Slavin, S; Zilberman, I | 1 |
| Chan, MC; Hunt, SA; Kwok, BW; Robbins, RC; Shiba, N; Valantine, HA | 1 |
| Arzouk, N; Beaudreuil, S; Charpentier, B; Durrbach, A; Hiesse, C; Kriaa, F; Snanoudj, R | 1 |
| Parekh, K; Patterson, GA; Trulock, E | 1 |
| Friend, P; Kreis, H; Mathew, T | 1 |
| André, N; Conrath, J; Roquelaure, B | 1 |
| Innocenti, F; Mani, S; Prado, M; Ramírez, J; Ratain, MJ; Schilsky, RL; Undevia, SD; Vogelzang, NJ | 1 |
| Hori, A; Kami, M; Kojima, R; Murashige, N; Ohnishi, M; Takaue, Y | 1 |
| Kahan, BD; Katz, SM; Knight, RJ; Lai, D; Schoenberg, L; Van Buren, CT; Yakupoglu, YK | 1 |
| Buell, JF; Gross, TG; Woodle, ES | 1 |
| Absi, L; Alamartine, E; Berthoux, F; Mariat, C; Thibaudin, D | 1 |
| Kiss, JE; Qu, L | 1 |
| Brault, Y; Burke, JT; Campistol, JM; Claesson, K; Eris, J; Friend, P; Hutchison, B; Kreis, H; Morales, JM; Neylan, JF; Oberbauer, R; Rostaing, L; Russ, G; Scarola, JA; Stallone, G | 1 |
| Edlich, F; Fischer, G | 1 |
| Alderden-Los, C; Beijnen, JH; Rosing, H; Schellens, JH; Sharma, A; Veltkamp, SA | 1 |
| Eisen, HJ; Ewald, GA; First, R; Fitzsimmons, W; Gao, J; Goldberg, LR; Kobashigawa, JA; Miller, LW; Russell, SD; Salm, K; Tolzman, D; Zucker, MJ | 1 |
| Balkman, CE; Beaulieu, BB; Lewis, LD; McEntee, MC; Page, RL; Rassnick, KM; Zgola, MM | 1 |
| Cheng, Y; Cherikh, WS; Hanto, DW; Kauffman, HM; McBride, MA | 1 |
| Morelon, E; Thaunat, O | 1 |
| Beijnen, JH; Binlich, F; Garrigue, JS; Huitema, AD; Lallemand, F; Lambert, G; Nol, A; Nuijen, B; Schellens, JH; Thijssen, B; Veltkamp, SA | 1 |
| Guillemin, F; Jay, N; Kessler, M; Molle, R | 1 |
| Dengler, T; Giese, T; Konstandin, M; Meuer, S; Schmidt, J; Sommerer, C; Zeier, M | 1 |
| Beijnen, JH; Fetell, MR; Huitema, AD; Nol, A; Rosing, H; Schellens, JH; Veltkamp, SA | 1 |
| Coakley, JC; Earl, JW; McLachlan, AJ; Nath, CE; Shaw, PJ | 1 |
| Joss, N; Junor, BJ; McMillan, MA; Rodger, RS | 1 |
| Campistol, JM; Gutiérrez-Dalmau, A | 1 |
| Ross, K | 1 |
| Ichimaru, N; Imamura, R; Imao, T; Isaka, Y; Kokado, Y; Namba, Y; Nonomura, N; Okumi, M; Okuyama, A; Takahara, S | 1 |
| Berneburg, M; Röcken, M; Weischer, M | 1 |
| Dantal, J; Pohanka, E | 1 |
| Valantine, H | 1 |
| Bies, RR; Dowell, JE; Egorin, MJ; Hollis, DR; Levine, EG; Lewis, LD; Millard, F; Miller, AA; Otterson, GA; Ratain, MJ; Relling, MV; Rosner, GL; Valdivieso, M | 1 |
| Barkholt, L; Bodegård, H; Böttiger, Y; Remberger, M; Ringdén, O | 1 |
| Abouelfath, A; Depont, F; Dupon, M; Dutronc, H; Galpérine, T; Giauque, E; Hébert, G; Moore, N; Ragnaud, JM; Valentino, R; Vargas, F | 1 |
| Alonso, A; Arias, M; González Molina, M; Sánchez-Plumed, JA | 1 |
| Járay, J; Végso, G | 1 |
| Ackerley, C; Clarke, DM; De Rosa, MF; Ito, S; Lingwood, C; Wang, B | 1 |
| Baron, F; Beguin, Y; Castermans, E; Cheynier, R; Geenen, V; Gothot, A; Herens, C; Meuris, N; Schaaf-Lafontaine, N; Seidel, L; Vanbellighen, JF; Willems, E | 1 |
| Ortiz de Frutos, FJ | 1 |
| Large, S; Parameshwar, J; Schofield, P | 1 |
| Mattison, DR; Olshan, AF; Zwanenburg, TS | 1 |
| Chavers, BM; Gillingham, KJ; Matas, AJ; Najarian, JS; Schmidt, WJ | 1 |
| Browne, BJ; Kahan, BD | 1 |
| Brugarolas, A; Cid, J; González-Manzano, R; Piasecki, CC | 1 |
| Davison, AM; Farmery, SM; Lodge, JP; London, NJ; Will, EJ | 1 |
| Bellamy, J; Benoit, G; Blanchet, P; Charpentier, B; Hiesse, C; Kriaa, F; Larue, JR | 1 |
| Ahn, C; Akman, S; Carroll, M; Doroshow, JH; Leong, L; Margolin, K; Morgan, RJ; Raschko, J; Scanlon, K; Somlo, G | 1 |
| Adler, KM; Brophy, NA; Fisher, GA; Halsey, J; Lum, BL; Sikic, BI; Yahanda, AM | 1 |
| Bors, V; Dorent, R; Gandjbakhch, I; Ghoussoub, JJ; Nataf, P; Pavie, A; Tedy, G; Vaissier, E | 1 |
| Bates, SE; Meadows, BJ; Regis, JI; Robey, RW; Scala, S; Zhan, Z | 1 |
| Bellamy, J; Benoit, G; Blanchet, P; Charpentier, B; Hiesse, C; Kriaa, F; Larue, JR; Rieu, P | 1 |
| Adler, KM; Brophy, NA; Fisher, GA; Halsey, J; Kaubisch, S; Lum, BL; Sikic, BI; Yahanda, AM | 1 |
| Bell, PR; Butt, ZA; Donnelly, PK; Kehinde, EO; Morgan, JD; Petermann, A; Veitch, PS | 1 |
| Chace, D; Fell, HP; Liggitt, D; Siegall, CB; Tepper, MA | 1 |
| Grabensee, B; Heering, P; Ritters, B | 1 |
| Penn, I | 2 |
| Bach, JF | 1 |
| Dunn, DL; Gillingham, K; Gruber, SA; Matas, AJ; Sothern, RB; Stephanian, E | 1 |
| Cowie, F; Pinkerton, CR | 1 |
| Chavers, B; Dunn, DL; Gillingham, K; Gruber, SA; Matas, AJ; Sothern, RB; Stephanian, E | 1 |
| Abeywickrama, KH; Abi-Rached, J; Dubertret, L; Grossman, R; Laburte, C | 1 |
| Bartlett, NL; Brophy, NA; Ehsan, MN; Fisher, GA; Halsey, J; Lum, BL; Sikic, BI | 1 |
| Mick, R; O'Brien, SM; Ratain, MJ; Safa, AR; Samuels, BL; Schilsky, RL; Vogelzang, NJ; Williams, SF | 1 |
| Kennedy, MJ | 1 |
| Sikic, BI | 1 |
| Barry, JM; Batiuk, TD; Bennett, WM; Meyer, MM; Norman, DJ; Tolzman, D | 1 |
| Bjarnason, G; Bunting, P; DeAngelis, C; Erlichman, C; Goodman, P; Kerr, IG; Moore, M; Thiessen, JJ; Walker, S | 1 |
| Dehlinger, J; Haverty, TP; Kahana, L; Monaco, A; Norman, DJ; Shield, CF; Stuart, FP; Thistlethwaite, JR; Van Horn, A; Wu, SC | 1 |
| Ho, VC; Zloty, DM | 1 |
| Amiss, N; Disney, AP; Mathew, TH; Sheil, AG | 1 |
| Bode, U; Brunkhorst, R; Frei, U; Hauss, J; Pichlmayr, R; Repp, H; Schindler, R; Vogt, P | 1 |
| Chou, TH; Dan, M; Flaherty, L; Redman, BG; Sensenbrenner, L; Uberti, J; Zalupski, M | 1 |
| Fisher, GA; Lum, BL; Sikic, BI | 1 |
| Hess, AD; Jones, RJ; Kennedy, MJ; Ruvolo, PP; Vogelsang, GB | 1 |
| Abi-Rached, J; Blanchet, F; Chevret, S; Dubertret, L; Grossman, RM | 1 |
| Chuang, FR; Hsieh, H; Hsu, KT; Huang, HF | 1 |
| Dijkmans, BA | 1 |
| Belli, L; Civati, G; Corbetta, G; Minetti, L; Ponticelli, C; Quarto di Palo, F; Tarantino, A; Vegeto, A | 1 |
| Tsuruo, T | 1 |
| Ríhová, B | 1 |
| Ferry, DR; Kerr, DJ; Traunecker, H | 1 |
| Bilgin, N; Büyükpamukçu, N; Karakayali, H | 1 |
| Hawkins, M; Mazumder, A; Obadina, M; Verma, U | 1 |
| Pollok, M; Schmidt, R; Schmitz-Rixen, T; Stippel, D | 1 |
| Bechstein, WO; Guckelberger, O; Jonas, S; Lobeck, H; Neuhaus, P; Neuhaus, R; Rayes, N; Riess, H; Schmidt, G; Tullius, SG; Vogl, T | 1 |
| Buszello, H; Jacobs, U; Klehr, HU; Paar, D | 1 |
| Bahner, U; Becker, P; Götz, R; Heidland, A; Steinle, A; Vamvakas, S | 1 |
| Crimmins, DL; Fracasso, PM; Hock, KG; Scott, MG | 1 |
| Hama, S; Kurisu, K; Saijo, N | 1 |
| Aozasa, K; Fujita, MQ; Hoshida, Y; Ichikawa, Y; Imanishi, M; Kurihara, K; Matsuno, T; Satoh, T; Tsukuma, H; Xu, N; Yasunaga, Y | 1 |
| Bakr, MA; el-Agroudy, A; el-Baz, M; el-Mekresh, M; Fouda, MA; Ghoneim, MA; Moustafa, F; Sally, S; Sobh, M; Wafa, E | 1 |
| Cripps, MC; Dahrouge, S; Davies, RA; Goel, R; Huan, S; Prosser, A; Soltys, K; Stewart, DJ; Tomiak, E; Yau, J | 1 |
| Arellano, F | 1 |
| Gooley, T; Hackman, RC; Ko, CW; Lee, SP; McDonald, GB; Myerson, D; Sale, GE; Schoch, HG; Shulman, HM | 1 |
| Eggert, J; Eising, EG; Gries, P; Scheulen, ME | 1 |
| Blancho, G; Cantarovich, D; Dantal, J; Dreno, B; Giral, M; Hourmant, M; Soulillou, JP | 1 |
| Belitsky, P; Boucher, A; Cole, E; Daloze, P; Dandavino, R; Halloran, P; Handa, P; Hendricks, L; Jeffrey, J; Keown, P; Landsberg, D; Lawen, J; Loertscher, R; Muirhead, N; Parfrey, P; Paul, L; Rush, D; Russell, D; Shoker, A; Stiller, C; Tan, A; Zaltzman, J | 1 |
| Baroni, A; Cusinato, S; Fabiano, M; Pozzato, M; Salomone, M; Serra, A; Vallero, A | 1 |
| Bellotti, G; Bocchi, EA; Fiorelli, A; Higuchi, ML; Jatene, A; Pileggi, F; Stolf, N; Uip, D; Vieira, ML | 1 |
| Hanibuchi, M; Nishioka, Y; Pai, K; Sone, S; Tsuruo, T; Yanagawa, H; Yano, S | 1 |
| Adamson, R; Andrews, J; Daily, PO; Dembitsky, W; Dychter, S; Gordon, J; Hoagland, P; Jaski, B; King, J; Moore, K; Moreno-Cabral, R; Obispo, E; Rich, M | 1 |
| Burgos, FJ; Crespo, M; Liaño, F; Marcén, R; Mateos, ML; Orofino, L; Ortuño, J; Pascual, J | 1 |
| Bisogno, G; Boddy, A; Cowie, F; Dick, G; Pinkerton, CR; Thomas, HD | 1 |
| Beijnen, JH; Meerum Terwogt, JM; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW | 1 |
| Bechstein, WO; Berg, T; Guckelberger, O; Hopf, U; Jonas, S; Müller, AR; Neuhaus, P; Platz, KP; Settmacher, U; Steinmüller, T; Tullius, SG | 1 |
| Emre, S; Guy, SR; Kelly, DM; Miller, CM; Schwartz, ME; Sheiner, PA | 1 |
| Brenot, R; Charvre, P; David, M; Eicher, JC; Gomes, MC; Tatou, E | 1 |
| Birkeland, SA | 1 |
| Bernelot Moens, HJ; Breedveld, FC; Dijkmans, BA; Goei The, HS; Hazes, JM; Houkes, I; Kluin, PM; Landewé, RB; Schild, F; van den Borne, BE; van der Heyden, PC; Vandenbroucke, JP; Zwinderman, AH | 1 |
| Bayer, R; Camarda, M; Kinch, L; Loutfi, S; Peace, D; Rad, N; Sosman, J; Stiff, PJ; Tan, S | 1 |
| Aschan, J; Carlens, S; Hägglund, H; Klaesson, S; Ljungman, P; Lönnqvist, B; Mattsson, J; Remberger, M; Ringdén, O; Svahn, BM; Winiarski, J | 1 |
| Chien, YS; Chuang, FR; Chung, HM; Hsieh, H; Hsu, KT | 1 |
| Ebisui, C; Fukunishi, T; Hanafusa, T; Ichikawa, Y; Kishikawa, H; Nagano, S; Okuyama, A; Yazawa, K | 1 |
| Nabel, GJ | 1 |
| de Vries, EG; Eriks-Fluks, L; Franssen, EJ; Hendrikse, NH; Hospers, GA; Vaalburg, W; van der Graaf, WT; Willemsen, AT | 1 |
| Biernat, M; Drop, D; Dziatkowiak, A; Garlicki, M; Olszewska, B; Przybyłowski, P; Rudziński, P; Wierzbicki, K | 1 |
| Breedveld, FC; Dijkmans, BA; Landewé, RB; van den Borne, BE | 1 |
| Hornig, F; Paul, C | 1 |
| Ahlers, C; Kreideweiss, S; Nordheim, A; Rühlmann, A | 1 |
| Beijnen, JH; Koopman, FJ; Malingré, MM; Meerum Terwogt, JM; Rosing, H; Schellens, JH; Swart, M; ten Bokkel Huinink, WW; van Tellingen, O | 1 |
| Becker, GJ; Jamil, B; Nicholls, K; Walker, RG | 1 |
| Beijnen, JH; Duchin, K; Huinink, WW; Koopman, FJ; Lieverst, J; Malingré, MM; Rosing, H; Schellens, JH; Swart, M; Terwogt, JM; van Tellingen, O | 1 |
| Bertz, H; Engelhardt, M; Finke, J; Hahn, J; Holler, E; Kunzmann, R; Reisser, S; Veelken, H; Wäsch, R | 1 |
| Henney, JE | 1 |
| Baker, SD; Britten, CD; Denis, LJ; Drengler, R; Duchin, K; Johnson, T; Kuhn, J; Rowinsky, EK; Siu, LL | 1 |
| Arita, S; Asano, T; Gunji, Y; Hayashi, H; Hori, S; Kashiwabara, H; Kenmochi, T; Nakajima, K; Ochiai, T; Sakamoto, K; Shimada, H; Suzuki, T; Takeda, A; Yokoyama, K | 1 |
| Chow, W; Coluzzi, P; Doroshow, JH; Hamasaki, V; Leong, LA; Margolin, KA; Morgan, RJ; Raschko, JW; Shibata, SI; Somlo, G; Synold, TW; ter Veer, A; Tetef, ML; Yen, Y | 1 |
| Beijnen, JH; Duchin, K; Huinink, WW; Koopman, FJ; Malingré, MM; Rosing, H; Schellens, JH; Swart, M; van Tellingen, O | 1 |
| Iñiguez, C; Larrodé, P; Mauri, JA; Mayordomo, JI; Morales, F; Trés, A | 1 |
| Beijnen, JH; Koopman, FJ; Malingré, MM; Richel, DJ; Rosing, H; Schellens, JH; Schot, ME; Ten Bokkel Huinink, WW | 1 |
| Arcese, W; Bacigalupo, A; Di Bona, E; Locasciulli, A; Locatelli, F | 1 |
| Beijnen, JH; Duchin, K; Koopman, FJ; Lieverst, J; Malingré, MM; Rosing, H; Schellens, JH; Swart, M; ten Bokkel Huinink, WW; van Tellingen, O | 2 |
| Sparreboom, A; van Zuylen, L; Verweij, J | 1 |
| Beijnen, JH; Malingré, MM; Schellens, JH | 1 |
| Blume, KG; Chauncey, T; Feinstein, L; Flowers, C; Georges, G; Kiem, HP; Little, MT; Maloney, D; Maris, M; McSweeney, PA; Nash, RA; Niederwieser, D; Radich, J; Sandmaier, B; Shizuru, J; Storb, R; Woolfrey, A; Zaucha, JM | 1 |
| Beijnen, JH; Duchin, K; Malingré, MM; Schellens, JH; Ten Bokkel Huinink, WW | 1 |
| Gotti, E; Locatelli, G; Perico, N; Remuzzi, G; Rota, G; Ruggenenti, P | 1 |
| Douglas, JF; McGeown, MG; Middleton, D | 1 |
| Chan, GZ; Kapoor, M | 1 |
| Beijnen, JH; Mackay, M; Malingré, MM; Schellens, JH; Ten Bokkel Huinink, WW | 1 |
| Bumgardner, GL; Hardie, I; Johnson, RW; Lin, A; Nashan, B; Pescovitz, MD; Ramos, E; Vincenti, F | 1 |
| Morel, D | 1 |
| Bardelmeijer, HA; Beijnen, JH; Koopman, FJ; Malingré, MM; Ouwehand, M; Rosing, H; Schellens, JH; Schot, ME; Ten Bokkel Huinink, WW; Van Tellingen, O | 1 |
| Gaston, RS | 1 |
| Hausberg, M; Kisters, K; Könecke, J; Kosch, M | 1 |
| Jia, B; Tang, Y; Zhang, Y | 1 |
| Amenábar, JJ; Gaínza, FJ; Gómez-Ullate, P; Lampreabe, I; Urbizu, JM; Zárraga, S | 1 |
| Barry, JM | 1 |
| White, KL | 1 |
| Ringdén, O | 1 |
| Carpentier, Y; Desoize, B; Gorisse, MC | 1 |
| Alder, KM; Brophy, NA; Fisher, GA; Gosland, MP; Halsey, J; Hardy, RI; Lum, BL; Sikic, BI; Yahanda, AM | 1 |
| Adler, KM; Brophy, NA; Ehsan, MN; Gosland, MP; Halsey, J; Jew, L; Kaubisch, S; Lum, BL; Sikic, BI; Yahanda, AM | 1 |
| Alberú, J; Angeles, A; Bordes-Aznar, J; Gabilondo, F; Mancilla, E; Orozco, R; Rosenblum, M | 1 |
| Alcaraz, A; Andreu, J; Carretero, P; Oppenheimer, F; Ricart, MJ; Talbot-Wright, R; Vilardell, J | 1 |
| Kurki, PT | 1 |
| Asano, T; Isono, K; Kashiwabara, H; Nakagouri, T; Ochiai, T; Sakamoto, K; Tokoro, Y; Yokoyama, T | 1 |
| Hess, AD; Jones, RJ; Morris, LE; Noga, SJ; Santos, GW; Vogelsang, GB; Yeager, AM | 1 |
| Cantarell, MC; Castelao, AM; Lauzurica, R; Oppenheimer, F; Puig, JM; Solá, R; Vilardell, J | 1 |
| Klaesson, S; Ljungman, P; Lönnqvist, B; Persson, U; Ringdén, O; Sundberg, B | 1 |
| Ryffel, B | 1 |
| Volkers, N | 1 |
| Remuzzi, G; Ruggenenti, P | 1 |
| Alexander, JW; Bhat, G; Bolce, R; First, MR; Hariharan, S; Munda, R; Penn, I; Ryckman, F; Schroeder, T | 1 |
55 review(s) available for cyclosporine and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction | 2015 |
Sarco/Endoplasmic Reticulum Calcium ATPase Inhibitors: Beyond Anticancer Perspective.
Topics: Animals; Antineoplastic Agents; Enzyme Inhibitors; Gene Regulatory Networks; Humans; Neoplasms; Protein Structure, Secondary; Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2020 |
CypA: A Potential Target of Tumor Radiotherapy and/or Chemotherapy.
Topics: Cyclophilin A; Cyclosporine; Humans; Immunosuppressive Agents; Neoplasms; Peptidylprolyl Isomerase | 2021 |
A potential role of the unfolded protein response in post-transplant cancer.
Topics: Biomarkers, Tumor; Cyclosporine; Humans; Immunosuppressive Agents; Neoplasms; Organ Transplantation; Unfolded Protein Response | 2017 |
Cell Migration Related to MDR-Another Impediment to Effective Chemotherapy?
Topics: Antibodies, Monoclonal; Antineoplastic Agents; ATP-Binding Cassette Transporters; Cancer-Associated Fibroblasts; Cell Movement; Cyclosporine; Disease Progression; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Neoplasms; Treatment Failure; Verapamil | 2018 |
Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results.
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Bacterial Agents; Anticonvulsants; Bandages; British Columbia; Comorbidity; Cyclosporine; Dermatologic Agents; Dermatology; Diabetes Mellitus; Dietetics; Disease Management; Female; Gout; Gout Suppressants; Humans; Immunocompromised Host; Immunoglobulins, Intravenous; Immunologic Factors; Intensive Care Units; Length of Stay; Male; Middle Aged; Mouth Mucosa; Neoplasms; Patient Care Team; Retrospective Studies; Seizures; Stevens-Johnson Syndrome; Surgery, Plastic; Torso | 2018 |
Lessons to Learn From Low-Dose Cyclosporin-A: A New Approach for Unexpected Clinical Applications.
Topics: Autoimmune Diseases; CD8-Positive T-Lymphocytes; Cyclosporine; Graft vs Host Disease; Humans; Immunomodulation; Immunosuppressive Agents; Lymphocyte Activation; Neoplasms; Organ Transplantation | 2019 |
Cyclophilin A as a target of Cisplatin chemosensitizers.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cisplatin; Cyclophilin A; Cyclophilins; Cyclosporine; Drug Resistance, Neoplasm; Humans; Neoplasms; Reactive Oxygen Species | 2014 |
Management of toxicities of immune checkpoint inhibitors.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Antineoplastic Agents; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Colitis; CTLA-4 Antigen; Cyclosporine; Diarrhea; Drug Eruptions; Humans; Immunosuppressive Agents; Infliximab; Ipilimumab; Kidney Neoplasms; Lung Neoplasms; Melanoma; Mycophenolic Acid; Neoplasms; Nivolumab; Pituitary Diseases; Programmed Cell Death 1 Receptor; Skin Neoplasms; Tacrolimus; Thyroiditis | 2016 |
Long-term safety of mycophenolate mofetil and cyclosporine: a review.
Topics: Adult; Cyclosporine; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Infections; Long-Term Care; Mycophenolic Acid; Neoplasms; Pregnancy; Psoriasis; Safety | 2008 |
Immunosuppressors as multidrug resistance reversal agents.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Ceramides; Clinical Trials as Topic; Cyclosporine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Immunosuppressive Agents; Molecular Structure; Neoplasms | 2010 |
Association between cancer and immunosuppressive therapy--analysis of selected studies in pemphigus and pemphigoid.
Topics: Azathioprine; Cyclophosphamide; Cyclosporine; Humans; Immunosuppressive Agents; Neoplasms; Pemphigoid, Bullous; Pemphigus; Retrospective Studies | 2010 |
Clinical insights for cancer outcomes in renal transplant patients.
Topics: Animals; Calcineurin Inhibitors; Cyclosporine; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Kidney Transplantation; Neoplasms; Risk Assessment; Risk Factors; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome | 2010 |
Thrombotic thrombocytopenic purpura: a hematological emergency.
Topics: ADAM Proteins; ADAMTS13 Protein; Antibodies, Monoclonal, Murine-Derived; Autoimmune Diseases; Cyclosporine; Female; Glucocorticoids; Hemolytic-Uremic Syndrome; Humans; Immunologic Factors; Immunosuppressive Agents; Infections; Neoplasms; Plasma Exchange; Platelet Transfusion; Pregnancy; Pregnancy Complications, Hematologic; Prognosis; Purpura, Thrombotic Thrombocytopenic; Renal Dialysis; Rituximab | 2012 |
[Progress in the study of some important natural bioactive cyclopeptides].
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Cyclosporine; Daptomycin; Depsipeptides; Gramicidin; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Molecular Structure; Neoplasms; Peptides, Cyclic; Quantitative Structure-Activity Relationship; Vancomycin | 2012 |
Use of cyclosporine in lung transplantation.
Topics: Acute Disease; Calcineurin Inhibitors; Chemistry, Pharmaceutical; Chronic Disease; Cyclosporine; Drug Therapy, Combination; Graft Rejection; Humans; Hypertension; Immunosuppressive Agents; Infections; Lung Transplantation; Neoplasms; Postoperative Complications | 2004 |
Malignancy after transplantation.
Topics: Azathioprine; Calcineurin Inhibitors; Carcinoma, Hepatocellular; Cyclosporine; Hepatitis, Viral, Human; Humans; Immunosuppressive Agents; Incidence; Kidney Transplantation; Lymphoproliferative Disorders; Mycophenolic Acid; Neoplasms; Sirolimus; Skin Neoplasms; Tacrolimus; Transplantation Immunology; Transplantation, Homologous | 2005 |
Thrombotic microangiopathy in transplantation and malignancy.
Topics: Cyclosporine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kidney Transplantation; Neoplasms; Plasma Exchange; Prognosis; Purpura, Thrombotic Thrombocytopenic; Risk Factors; Tacrolimus; Treatment Outcome | 2005 |
Pharmacological targeting of catalyzed protein folding: the example of peptide bond cis/trans isomerases.
Topics: Animals; Cardiovascular Diseases; Catalysis; Cyclophilins; Cyclosporine; Drug Design; Enzyme Inhibitors; Humans; Immunosuppressive Agents; Inflammation; Neoplasms; NIMA-Interacting Peptidylprolyl Isomerase; Peptidylprolyl Isomerase; Protein Folding; Reperfusion Injury; Skin Diseases; Tacrolimus Binding Protein 1A | 2006 |
Post-transplant de novo malignancies in renal transplant recipients: the past and present.
Topics: Antilymphocyte Serum; Azathioprine; Cyclosporine; Europe; Female; History, 20th Century; History, 21st Century; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Neoplasms; Ohio; Registries; Sirolimus; Tacrolimus; United States | 2006 |
The role of proliferation signal inhibitors in post-transplant malignancies.
Topics: Animals; Calcineurin Inhibitors; Cyclosporine; Humans; Immunosuppressive Agents; Kidney Transplantation; Lymphoproliferative Disorders; Neoplasms; Protein Kinases; PTEN Phosphohydrolase; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2007 |
Calcineurin inhibitors and rapamycin: cancer protection or promotion?
Topics: Calcineurin Inhibitors; Carcinogens; Cyclosporine; DNA Repair; Humans; Immunosuppressive Agents; Models, Biological; Neoplasms; Protein Kinases; Sirolimus; Tacrolimus; TOR Serine-Threonine Kinases; Ultraviolet Rays | 2007 |
Malignancies in renal transplantation: an unmet medical need.
Topics: Cyclosporine; Humans; Immunosuppressive Agents; Kidney Transplantation; Lymphoproliferative Disorders; Neoplasms; Risk Factors | 2007 |
Sirolimus, the first mTOR inhibitor.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Atherosclerosis; Bone Marrow Diseases; Cell Division; Clinical Trials as Topic; Cyclosporine; Graft Rejection; Graft vs Host Disease; Humans; Immunosuppressive Agents; Kidney Diseases; Kidney Transplantation; Lymphocyte Subsets; Mice; Multicenter Studies as Topic; Muscle, Smooth, Vascular; Neoplasms; Postoperative Complications; Sirolimus; TOR Serine-Threonine Kinases; Wound Healing | 2006 |
[Malignant tumors following renal transplantation].
Topics: Adrenal Cortex Hormones; Azathioprine; Calcineurin Inhibitors; Cyclosporine; Humans; Immunosuppressive Agents; Incidence; Kidney Transplantation; Lymphoproliferative Disorders; Muromonab-CD3; Neoplasms; Prognosis; Sarcoma, Kaposi; Skin Neoplasms; Tacrolimus | 2007 |
[Atopic dermatitis and tacrolimus in adults].
Topics: Adrenal Cortex Hormones; Adult; Child; Clinical Trials as Topic; Cost-Benefit Analysis; Cyclosporine; Dermatitis, Atopic; Humans; Immunosuppressive Agents; Meta-Analysis as Topic; Middle Aged; Neoplasms; Pruritus; Retrospective Studies; Spain; Tacrolimus; Young Adult | 2008 |
International Commission for Protection Against Environmental Mutagens and Carcinogens. Cyclosporine A: review of genotoxicity and potential for adverse human reproductive and developmental effects. Report of a Working Group on the genotoxicity of cyclosp
Topics: Animals; Azathioprine; Chromosome Aberrations; Cyclosporine; Fetus; Humans; Neoplasms; Prednisone; Reproduction | 1994 |
Transplantation 1994: the year in review.
Topics: Clinical Trials as Topic; Cyclosporine; Disease Susceptibility; Emulsions; Global Health; Graft Rejection; Histocompatibility Testing; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Infections; Life Tables; Multicenter Studies as Topic; Neoplasms; Organ Transplantation; Postoperative Complications; Public Opinion; Tissue and Organ Procurement; Treatment Outcome | 1994 |
Clinical reversal of multidrug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Clinical Trials as Topic; Cyclosporine; Drug Resistance, Multiple; Etoposide; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Neoplasms; Paclitaxel; Pharmaceutical Preparations; Verapamil | 1994 |
Chemoresistance in the clinic: overview 1994.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Dipyridamole; Drug Resistance, Multiple; Glutathione; Humans; Neoplasms; Nifedipine; Verapamil | 1994 |
Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Clinical Trials as Topic; Cyclosporine; Drug Resistance; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Membrane Glycoproteins; Neoplasm Proteins; Neoplasms | 1993 |
Posttransplant malignancies in pediatric organ transplant recipients.
Topics: Adolescent; Adult; Age Factors; Child; Cyclosporine; Humans; Immunosuppression Therapy; Lymphoma; Neoplasms; Transplantation Immunology | 1994 |
Lessons for transplant immunosuppression from the usage of cyclosporine in autoimmune diseases.
Topics: Autoimmune Diseases; B-Lymphocytes; Cyclosporine; Humans; Immunosuppression Therapy; Incidence; Neoplasms; Postoperative Complications; T-Lymphocytes; Transplantation Immunology | 1994 |
Induced autologous graft-versus-host disease for the treatment of cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclosporine; Female; Graft vs Host Disease; Humans; Immunotherapy; Interferon-gamma; Lymphoma; Mice; Neoplasms; Neoplasms, Experimental; Rats; Transplantation, Autologous | 1994 |
Immunosuppressive agents in dermatology.
Topics: Azathioprine; Clinical Protocols; Cyclophosphamide; Cyclosporine; Humans; Immunosuppressive Agents; Neoplasms; Skin Diseases | 1993 |
The reversal of multidrug resistance.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; Clinical Trials as Topic; Cyclosporine; Drug Resistance, Multiple; Humans; Neoplasms | 1995 |
Antitumor activity of syngeneic/autologous graft-versus-host disease.
Topics: Animals; Bone Marrow Transplantation; Cyclosporine; Graft vs Host Disease; Histocompatibility Antigens Class II; Humans; Immunotherapy; Neoplasms; Transplantation, Autologous | 1995 |
Safety aspects of cyclosporin in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Drug Interactions; Guidelines as Topic; Humans; Kidney; Neoplasms | 1995 |
[Chemotherapeutic approaches against drug resistant tumors].
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; Cyclosporine; Drug Resistance, Multiple; Drug Therapy, Combination; Humans; Neoplasms; Quinolines | 1996 |
Antibody-targeted polymer-bound drugs.
Topics: Acrylamides; Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antineoplastic Agents; Chlorophyllides; Clinical Trials as Topic; Cyclosporine; Daunorubicin; Doxorubicin; Histocompatibility Antigens Class II; Humans; Immune System Diseases; Immunoconjugates; Immunosuppressive Agents; Lysosomes; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Polymethacrylic Acids; Porphyrins; Radiation-Sensitizing Agents; T-Lymphocyte Subsets; Thy-1 Antigens; Tissue Distribution | 1995 |
Clinical trials of P-glycoprotein reversal in solid tumours.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Clinical Trials as Topic; Cyclosporine; Drug Resistance, Neoplasm; Humans; Neoplasm Proteins; Neoplasms; Quinolines; Tamoxifen; Verapamil | 1996 |
Immunomodulation following chemotherapy.
Topics: Animals; Bone Marrow Transplantation; Cyclosporine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferons; Interleukin-2; Neoplasms | 1996 |
[Cyclosporine as drug resistance modifiers; mechanism and clinical investigation].
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Clinical Trials as Topic; Cyclosporine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Immunosuppressive Agents; Neoplasms | 1997 |
[Peripheral nervous system neurotoxicity secondary to chemotherapy treatment] .
Topics: Anti-HIV Agents; Antineoplastic Agents; Cyclosporine; Depsipeptides; Docetaxel; Doxorubicin; Humans; Neoplasms; Neuromuscular Diseases; Oligopeptides; Organoplatinum Compounds; Paclitaxel; Peripheral Nervous System Diseases; Procarbazine; Reverse Transcriptase Inhibitors; Suramin; Taxoids; Vinca Alkaloids | 2000 |
Role of formulation vehicles in taxane pharmacology.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chemistry, Pharmaceutical; Cyclosporine; Drug Hypersensitivity; Drug Resistance, Multiple; Glycerol; Humans; Micelles; Neoplasms; Nervous System Diseases; Paclitaxel; Polysorbates; Surface-Active Agents | 2001 |
Oral delivery of taxanes.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cyclosporine; Cyclosporins; Docetaxel; Humans; Mice; Mice, Knockout; Neoplasms; Paclitaxel; Taxoids | 2001 |
Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
Topics: Adult; Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclosporine; Disease Progression; Dogs; Forecasting; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Methotrexate; Middle Aged; Mycophenolic Acid; Neoplasms; Prednisone; Radiation Chimera; T-Lymphocytes, Cytotoxic; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2001 |
Malignancy and renal disease.
Topics: Acute Kidney Injury; Antineoplastic Agents; Bone Marrow Transplantation; Cisplatin; Cyclosporine; Hepatorenal Syndrome; Humans; Kidney Diseases; Methotrexate; Multiple Myeloma; Neoplasms; Renal Replacement Therapy | 2001 |
Maintenance immunosuppression in the renal transplant recipient: an overview.
Topics: Black People; Calcineurin Inhibitors; Cyclosporine; Drug Interactions; Drug Monitoring; Female; Graft Rejection; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Transplantation; Long-Term Care; Neoplasms; Opportunistic Infections; Patient Compliance; Practice Patterns, Physicians'; Pregnancy; Pregnancy Complications; Prenatal Exposure Delayed Effects | 2001 |
[Presentation of cancers in recipients of a solid-organ transplant].
Topics: Carcinogens; Cell Transformation, Neoplastic; Cyclosporine; Genetic Predisposition to Disease; Humans; Immunocompromised Host; Immunosuppression Therapy; Incidence; Kidney Transplantation; Lymphoproliferative Disorders; Melanoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Neoplastic Stem Cells; Oncogenes; Postoperative Complications; Prevalence; Recurrence; Risk; Sarcoma, Kaposi; Skin Neoplasms; Transplantation; Tumor Virus Infections; Ultraviolet Rays | 2001 |
Immunosuppressive drugs in renal transplantation. A review of the regimens.
Topics: Antilymphocyte Serum; Azathioprine; Cyclosporine; Graft Rejection; Graft Survival; Humans; Immunocompromised Host; Immunosuppressive Agents; Infections; Kidney Transplantation; Neoplasms; Prednisolone; Tacrolimus | 1992 |
Safety aspects of the long term cyclosporin A therapy.
Topics: Arthritis, Rheumatoid; Cyclosporine; Humans; Hypertension; Immune Tolerance; Kidney; Neoplasms; Prognosis; Time Factors | 1992 |
Autologous graft-versus-host disease: a new frontier in immunotherapy.
Topics: Animals; Autoimmunity; Bone Marrow Transplantation; Cyclosporine; Graft vs Host Disease; Humans; Immunotherapy; Neoplasms; T-Lymphocyte Subsets; Transplantation, Autologous | 1992 |
The carcinogenicity of ciclosporin.
Topics: Animals; Carcinogens; Cyclosporine; Humans; Immunosuppressive Agents; Neoplasms | 1992 |
Thrombotic microangiopathies.
Topics: Adult; Child; Cyclosporine; Endothelium, Vascular; Female; Genetic Predisposition to Disease; Hemolytic-Uremic Syndrome; Humans; Immunosuppressive Agents; Infections; Kidney; Kidney Transplantation; Microcirculation; Neoplasms; Plasma Exchange; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy Complications, Hematologic; Purpura, Thrombotic Thrombocytopenic; Thrombosis | 1991 |
57 trial(s) available for cyclosporine and Neoplasms
| Article | Year |
|---|---|
A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4).
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Cyclosporine; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunologic Factors; Immunosuppressive Agents; Male; Middle Aged; Neoplasms; Prognosis; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Rituximab; Survival Rate; Young Adult | 2015 |
Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin.
Topics: Adult; Aged; Alanine Transaminase; Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Bone Marrow Neoplasms; Carcinoma; Cell Adhesion Molecules; Chemical and Drug Induced Liver Injury; Cyclosporine; Drug Interactions; Epithelial Cell Adhesion Molecule; Female; Half-Life; Humans; Immunoconjugates; Infusions, Intravenous; Lethal Dose 50; Macaca fascicularis; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Middle Aged; Neoplasm Micrometastasis; Neoplasms; Treatment Outcome | 2015 |
Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Topics: Abatacept; Adult; Calcineurin Inhibitors; Cyclosporine; Drug Substitution; Female; Graft Rejection; Graft Survival; Humans; Immunocompromised Host; Immunosuppressive Agents; Infections; Kidney Transplantation; Lymphoproliferative Disorders; Male; Middle Aged; Mortality; Neoplasms; Tacrolimus; Treatment Outcome | 2017 |
The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.
Topics: Adult; Australia; Calcineurin Inhibitors; Cyclosporine; Drug Therapy, Combination; Everolimus; Female; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Incidence; Intention to Treat Analysis; Kaplan-Meier Estimate; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Neoplasms; New Zealand; Proportional Hazards Models; Protective Factors; Registries; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Cyclosporine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycerol; Humans; Immunosuppressive Agents; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel | 2008 |
A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis.
Topics: Adult; Alefacept; CD4 Lymphocyte Count; Cyclosporine; Dermatologic Agents; Drug Administration Routes; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Immunologic Factors; Immunosuppressive Agents; Infections; Lymphopenia; Male; Methotrexate; Middle Aged; Neoplasms; Psoriasis; Recombinant Fusion Proteins; Retinoids; Retreatment; Treatment Outcome; Ultraviolet Therapy | 2008 |
20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients.
Topics: Antilymphocyte Serum; Azathioprine; Combined Modality Therapy; Cyclosporine; Cytomegalovirus Infections; Follow-Up Studies; Graft Rejection; Graft Survival; Humans; Immunologic Factors; Immunosuppressive Agents; Kidney Transplantation; Neoplasms; Postoperative Complications; Prednisone; Survival Analysis; Time Factors | 2008 |
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Topics: Adolescent; Adult; Aged; Biopsy; Calcineurin Inhibitors; Cyclosporine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Neoplasms; Prospective Studies; Sirolimus; Tacrolimus; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2009 |
Cyclosporine withdrawal improves long-term graft survival in renal transplantation.
Topics: Azathioprine; Cause of Death; Cyclosporine; Drug Administration Schedule; Female; Glomerular Filtration Rate; Graft Rejection; Graft Survival; Histocompatibility Testing; Humans; Immunosuppressive Agents; Kidney Transplantation; Liver Function Tests; Male; Neoplasms; Patient Selection; Prednisolone; Survival Analysis; Survivors | 2009 |
Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia.
Topics: Anemia, Aplastic; Antilymphocyte Serum; Blood Cell Count; Cyclosporine; Disease-Free Survival; Drug Therapy, Combination; Follow-Up Studies; Hemoglobinuria, Paroxysmal; Humans; Immunosuppressive Agents; Kinetics; Leukemia; Methylprednisolone; Myelodysplastic Syndromes; Neoplasms; Recurrence; Remission Induction; Salvage Therapy; Survival Rate | 2003 |
Use of rapamycin slows progression of cardiac transplantation vasculopathy.
Topics: Arterial Occlusive Diseases; Autoantibodies; Cardiac Catheterization; Cohort Studies; Coronary Artery Disease; Cyclosporine; Disease Progression; Female; Graft Rejection; Heart Transplantation; Humans; Immunosuppressive Agents; Infections; Male; Middle Aged; Neoplasms; Prospective Studies; Renal Insufficiency; Sirolimus; Survival Analysis; Treatment Outcome | 2003 |
Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy.
Topics: Adult; Azathioprine; Biopsy; Cardiovascular Diseases; Cause of Death; Chronic Disease; Cyclosporine; Dose-Response Relationship, Drug; Female; Graft Survival; Humans; Immunosuppressive Agents; Kidney; Kidney Diseases; Kidney Transplantation; Male; Middle Aged; Neoplasms; Patient Compliance; Proteinuria; Risk Factors; Survival Analysis; Time Factors; Transplantation, Homologous | 2003 |
A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation.
Topics: Adult; Busulfan; Cyclosporine; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasms; Patient Selection; Pilot Projects; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endpoint Determination; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Half-Life; Humans; Hypnotics and Sedatives; Immunosuppressive Agents; Irinotecan; Lymphoma; Male; Middle Aged; Neoplasms; Phenobarbital | 2004 |
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.
Topics: Adult; Cyclosporine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Immunosuppressive Agents; Incidence; Kidney Transplantation; Neoplasms; Risk Assessment; Sirolimus | 2006 |
Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report.
Topics: Adult; Antiviral Agents; Cyclosporine; Cytomegalovirus Infections; Drug Therapy, Combination; Female; Graft Rejection; Heart Transplantation; Heart-Lung Transplantation; Humans; Hypolipidemic Agents; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Neoplasms; Patient Selection; Postoperative Complications; Sirolimus; Treatment Outcome; United States | 2006 |
Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing dogs.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cyclosporine; Docetaxel; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Male; Neoplasms; Taxoids | 2006 |
A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cyclosporine; Disease Progression; Drug Administration Schedule; Drug Delivery Systems; Emulsifying Agents; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Safety; Solubility; Tissue Distribution; Treatment Outcome | 2006 |
Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capsules; Chemistry, Pharmaceutical; Cyclosporine; Drinking; Drug Administration Schedule; Female; Humans; Infant; Infant, Newborn; Male; Neoplasms; Paclitaxel | 2007 |
Amphotericin B dose optimization in children with malignant diseases.
Topics: Adolescent; Amphotericin B; Antifungal Agents; Body Weight; Child; Child, Preschool; Computer Simulation; Creatinine; Cyclosporine; Deoxycholic Acid; Drug Combinations; gamma-Glutamyltransferase; Humans; Immunosuppressive Agents; Infant; Kidney Diseases; Microbial Sensitivity Tests; Models, Biological; Mycoses; Neoplasms; Risk Factors; Urea | 2007 |
Randomized study comparing cyclosporine with azathioprine one year after renal transplantation-15-year outcome data.
Topics: Adult; Azathioprine; Cardiovascular Diseases; Cause of Death; Cyclosporine; Follow-Up Studies; Humans; Immunosuppressive Agents; Kidney Transplantation; Neoplasms; Postoperative Complications; Retrospective Studies; Sepsis; Survival; Survival Analysis; Time Factors | 2007 |
Evidence for neo-generation of T cells by the thymus after non-myeloablative conditioning.
Topics: Adult; Aged; Anesthesia Recovery Period; CD8-Positive T-Lymphocytes; Cyclosporine; Female; Flow Cytometry; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunosuppressive Agents; Lymphocyte Depletion; Male; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Neoplasms; Peripheral Blood Stem Cell Transplantation; Receptors, Antigen, T-Cell, alpha-beta; Thymus Gland; Time Factors; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2008 |
Cyclosporin A and doxorubicin-ifosfamide in resistant solid tumours: a phase I and an immunological study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Cyclosporine; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Immunity, Cellular; Lymphocyte Count; Lymphocyte Subsets; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Remission Induction | 1995 |
Phase I trial of carboplatin and infusional cyclosporin in advanced malignancy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Cyclosporine; Drug Resistance; Feasibility Studies; Female; Humans; Infusions, Intravenous; Kidney Diseases; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Thrombocytopenia; Tumor Cells, Cultured | 1995 |
Clinical reversal of multidrug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Clinical Trials as Topic; Cyclosporine; Drug Resistance, Multiple; Etoposide; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Neoplasms; Paclitaxel; Pharmaceutical Preparations; Verapamil | 1994 |
Chemoresistance in the clinic: overview 1994.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Dipyridamole; Drug Resistance, Multiple; Glutathione; Humans; Neoplasms; Nifedipine; Verapamil | 1994 |
Triple therapy and incidence of de novo cancer in renal transplant recipients.
Topics: Adolescent; Adult; Aged; Azathioprine; Child; Cyclosporine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunosuppression Therapy; Kidney Transplantation; Male; Middle Aged; Neoplasms; Prednisolone; Prospective Studies; Time Factors | 1994 |
Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Chronic Disease; Creatinine; Cyclosporine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension; Kidney Diseases; Male; Middle Aged; Neoplasms; Psoriasis; Remission Induction; Treatment Outcome | 1994 |
Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.
Topics: Adult; Aged; Cyclosporine; Doxorubicin; Drug Administration Schedule; Drug Resistance; Female; Humans; Male; Middle Aged; Neoplasms; Treatment Outcome | 1994 |
Modulation of vinblastine resistance with cyclosporine: a phase I study.
Topics: Adult; Aged; Cyclosporine; Drug Interactions; Drug Resistance; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Vinblastine | 1993 |
Incidence and type of cancer following the use of OKT3: a single center experience with 557 organ transplants.
Topics: Adenoma, Bile Duct; Age Factors; Azathioprine; Cyclosporine; Follow-Up Studies; Humans; Immunosuppression Therapy; Incidence; Kidney Transplantation; Lymphoma; Male; Muromonab-CD3; Neoplasms; Prostatic Neoplasms; Retrospective Studies; Skin Neoplasms; Thyroid Neoplasms | 1993 |
Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Creatinine; Cyclosporine; Doxorubicin; Drug Administration Schedule; Humans; Infusions, Intravenous; Neoplasms; Neutropenia; Thrombocytopenia | 1993 |
A randomized clinical trial of induction therapy with OKT3 in kidney transplantation.
Topics: Adolescent; Adult; Aged; Antibody Formation; Azathioprine; Child; Cyclosporine; Drug Administration Schedule; Female; Graft Rejection; Graft Survival; Humans; Infections; Kidney Transplantation; Male; Methylprednisolone; Middle Aged; Muromonab-CD3; Neoplasms; Prospective Studies; Succinates; Succinic Acid; Time Factors; Transplantation Immunology | 1993 |
Phase I trial of sequential cyclophosphamide, cyclosporin A, and interferon-alpha in patients with cancer: attempt to induce autologous graft-versus-host reaction to elicit an antitumor response.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Cyclosporine; Cytotoxicity Tests, Immunologic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Graft vs Host Reaction; Humans; Interferon-alpha; Male; Middle Aged; Neoplasms; Transplantation, Autologous | 1995 |
Long-term safety of cyclosporine in the treatment of psoriasis.
Topics: Adolescent; Adult; Aged; Cyclosporine; Female; Humans; Hypertension; Immunosuppressive Agents; Kidney; Male; Middle Aged; Neoplasms; Psoriasis; Time Factors | 1996 |
Randomized study with cyclosporine in kidney transplantation: 10-year follow-up.
Topics: Adolescent; Adult; Azathioprine; Cataract; Child; Creatinine; Cyclosporine; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Infections; Kidney Diseases; Kidney Transplantation; Life Tables; Male; Middle Aged; Neoplasms; Postoperative Complications; Survival Rate; Treatment Outcome | 1996 |
HPLC method for monitoring SDZ PSC 833 in whole blood.
Topics: Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Cross Reactions; Cyclosporine; Cyclosporins; Drug Monitoring; Fluorescence Polarization Immunoassay; Humans; Immunosuppressive Agents; Neoplasms; Paclitaxel; Reproducibility of Results | 1997 |
Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens.
Topics: Adolescent; Adult; Aged; Area Under Curve; Azathioprine; Cyclosporine; Drug Administration Schedule; Drug Therapy, Combination; Female; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Neoplasms; Prednisolone; Prospective Studies; Risk Factors; Statistics as Topic | 1998 |
Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients: a report of the Canadian Neoral Renal Study Group.
Topics: Administration, Oral; Adult; Blood Pressure; Canada; Communicable Diseases; Cyclosporine; Emulsions; Female; Follow-Up Studies; Humans; Kidney Transplantation; Living Donors; Male; Middle Aged; Neoplasms; Postoperative Complications; Prospective Studies; Time Factors; Tissue Donors | 1998 |
High-dose cyclosporin with etoposide--toxicity and pharmacokinetic interaction in children with solid tumours.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclosporine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Etoposide; Female; Humans; Male; Neoplasms | 1998 |
Co-administration of cyclosporin enables oral therapy with paclitaxel.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cyclosporine; Drug Therapy, Combination; Humans; Infusions, Intravenous; Mice; Mice, Knockout; Neoplasms; Paclitaxel | 1998 |
Five-year follow-up of tacrolimus as primary immunosuppressant after liver transplantation.
Topics: Adolescent; Adult; Aged; Azathioprine; Cyclosporine; Drug Therapy, Combination; Follow-Up Studies; Graft Survival; Humans; Immunosuppressive Agents; Liver Transplantation; Methylprednisolone; Middle Aged; Neoplasms; Postoperative Complications; Survival Rate; Tacrolimus; Time Factors | 1998 |
High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a phase I clinical trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bone Marrow Transplantation; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Drug Resistance, Neoplasm; Female; Humans; Immunosuppressive Agents; Kidney Diseases; Male; Middle Aged; Mitoxantrone; Neoplasms; Transplantation, Autologous | 1995 |
Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Biotransformation; Cyclosporine; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel | 1999 |
Phase I and pharmacokinetic study of oral paclitaxel.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel | 2000 |
Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclosporine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukapheresis; Male; Melphalan; Methotrexate; Middle Aged; Neoplasms; Prospective Studies; Survival Analysis; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation Tolerance; Vidarabine | 2000 |
A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclosporine; Dipyridamole; Etoposide; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasms; Prochlorperazine; Treatment Outcome; Vasodilator Agents | 2000 |
Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cyclosporine; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2001 |
Treatment of aplastic anaemia with granulocyte-colony stimulating factor and risk of malignancy. Italian Aplastic Anaemia Study Group.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Antilymphocyte Serum; Child; Child, Preschool; Cyclosporine; Drug Therapy, Combination; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hemoglobinuria, Paroxysmal; Humans; Immunosuppressive Agents; Infant; Leukemia; Male; Middle Aged; Mouth Neoplasms; Myelodysplastic Syndromes; Neoplasms; Risk Factors; Survival Analysis; Treatment Outcome | 2001 |
The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carcinoma, Small Cell; Cyclosporine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel; Premedication; Stomach Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms | 2001 |
A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Cyclosporine; Drug Combinations; Female; Humans; Immunosuppressive Agents; Injections, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel | 2001 |
The kidney transplant program at the Bergamo Center.
Topics: Academic Medical Centers; Animals; Calcineurin; Cyclosporine; Genetic Therapy; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; In Vitro Techniques; Infections; Italy; Kidney Transplantation; Mycophenolic Acid; Neoplasms; Randomized Controlled Trials as Topic; Renal Artery Obstruction; Survival Rate; Swine; Tissue and Organ Procurement; Transplantation, Heterologous | 2000 |
Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.
Topics: Acute Disease; Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Cyclosporine; Daclizumab; Graft Rejection; Graft Survival; Humans; Immunoglobulin G; Immunosuppressive Agents; Kidney Transplantation; Lymphoproliferative Disorders; Neoplasms; Receptors, Interleukin-2; Survival Rate; Time Factors | 2001 |
The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Area Under Curve; Cyclosporine; Drug Combinations; Feces; Glycerol; Humans; Intestinal Absorption; Neoplasms; Paclitaxel; Pharmaceutical Vehicles; Polysorbates; Solvents | 2001 |
Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Drug Resistance; Etoposide; Female; Gene Expression; Humans; Male; Middle Aged; Neoplasms | 1992 |
Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.
Topics: Adult; Aged; Cyclosporine; Drug Interactions; Drug Resistance; Etoposide; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms | 1992 |
Malignant neoplasms in renal transplant patients: a 24-year experience.
Topics: Azathioprine; Cyclosporine; Drug Therapy, Combination; Female; Humans; Immunosuppression Therapy; Kidney Transplantation; Male; Methylprednisolone; Mexico; Neoplasms; Prednisone; Retrospective Studies | 1992 |
150 other study(ies) available for cyclosporine and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Potent and Nontoxic Chemosensitizer of P-Glycoprotein-Mediated Multidrug Resistance in Cancer: Synthesis and Evaluation of Methylated Epigallocatechin, Gallocatechin, and Dihydromyricetin Derivatives.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Catechin; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flavonols; Humans; Methylation; Models, Molecular; Molecular Structure; Neoplasm Proteins; Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured | 2015 |
Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2).
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; Camptothecin; Carbolines; Cell Line; Dogs; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Proteins; Neoplasms | 2016 |
Optimization of the
Topics: Animals; Antineoplastic Agents; Blood; Caspase Inhibitors; Cell Line, Tumor; Female; Half-Life; Humans; Mice, Inbred BALB C; Mice, SCID; Microsomes, Liver; Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein; Neoplasms; Pyrazoles; Pyrimidines; Rats, Sprague-Dawley; Sheep; Urea; Xenograft Model Antitumor Assays | 2020 |
Risk of malignancy in patients with psoriasis receiving systemic medications: A nested case-control study.
Topics: Adalimumab; Biological Products; Case-Control Studies; Cyclosporine; Dermatologic Agents; Etanercept; Humans; Methotrexate; Neoplasms; Psoriasis; Ustekinumab | 2022 |
Low-dose Pimecrolimus, an FDA-approved Calcineurin Inhibitor, Sensitizes Drug-resistant Cancer Cells
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcineurin Inhibitors; Cyclosporine; Humans; Neoplasms; Rhodamine 123; Tacrolimus | 2023 |
Adding cyclosporin A to eltrombopag for aplastic anemia secondary to chemotherapy for solid cancers.
Topics: Anemia, Aplastic; Benzoates; Cyclosporine; Humans; Immunosuppressive Agents; Neoplasms | 2023 |
Tumour induction in BALB/c mice for imaging studies: An improved protocol.
Topics: Animals; Cyclophosphamide; Cyclosporine; Humans; Ketoconazole; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms | 2023 |
Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality.
Topics: Adalimumab; Alkylating Agents; Antimetabolites; Azathioprine; Calcineurin Inhibitors; Cohort Studies; Cyclosporine; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Infliximab; Methotrexate; Mycophenolic Acid; Neoplasms; Retrospective Studies; Tumor Necrosis Factor Inhibitors | 2023 |
The 28-year incidence of de novo malignancies after liver transplantation: A single-center analysis of risk factors and mortality in 1616 patients.
Topics: Adult; Age Factors; Aged; Cyclosporine; End Stage Liver Disease; Female; Follow-Up Studies; Graft Rejection; Humans; Immunosuppressive Agents; Incidence; Kaplan-Meier Estimate; Liver Transplantation; Male; Middle Aged; Neoplasms; Prognosis; Proportional Hazards Models; Prospective Studies; Risk Factors; Smoking; Tacrolimus; Young Adult | 2017 |
The use of electronic-neutral penetrating peptides cyclosporin A to deliver pro-apoptotic peptide: A possibly better choice than positively charged TAT.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell-Penetrating Peptides; Cyclosporine; Drug Delivery Systems; Female; HeLa Cells; Humans; MCF-7 Cells; Mice; Mice, Nude; Mitochondrial Membranes; Neoplasms; Oligopeptides; Peptide Fragments; Peptides; tat Gene Products, Human Immunodeficiency Virus; Xenograft Model Antitumor Assays | 2017 |
Ciclosporin A as a Reversal Agent Against Concurrent Multidrug Resistance in Tumors with Nanobubbles.
Topics: Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cyclosporine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Nanostructures; Neoplasms | 2018 |
Enhanced anticancer effect of MAP30-S3 by cyclosproin A through endosomal escape.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cyclosporine; Drug Synergism; Endosomes; HeLa Cells; Humans; Neoplasms; Recombinant Fusion Proteins; Ribosomal Proteins; Ribosome Inactivating Proteins, Type 2 | 2018 |
A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Death; Cell Line, Tumor; Cyclosporine; ErbB Receptors; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction | 2019 |
Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study.
Topics: Adult; Aged; Anemia, Aplastic; Antilymphocyte Serum; Bone Marrow Diseases; Bone Marrow Failure Disorders; Cyclophosphamide; Cyclosporine; Drug Evaluation; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Histocompatibility; HLA Antigens; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Mycophenolic Acid; Neoplasms; Retrospective Studies; T-Lymphocytes; Tissue Donors | 2019 |
Synthesis and Characterization of Bodipy-FL-Cyclosporine A as a Substrate for Multidrug Resistance-Linked P-Glycoprotein (ABCB1).
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Azoles; Boron Compounds; Cyclosporine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Dyes; HeLa Cells; Humans; Inhibitory Concentration 50; Microscopy, Fluorescence; Molecular Docking Simulation; Molecular Imaging; Molecular Probes; Neoplasms; Nitrobenzenes; Quinolines; Recombinant Proteins | 2019 |
High graft protection and low incidences of infections, malignancies and other adverse effects with intra-operative high dose ATG-induction: a single centre cohort study of 760 cases.
Topics: Adult; Antilymphocyte Serum; Azathioprine; Cohort Studies; Cyclosporine; Cytomegalovirus Infections; Female; Graft Survival; Humans; Immunosuppressive Agents; Intraoperative Period; Kaplan-Meier Estimate; Kidney Transplantation; Lymphoproliferative Disorders; Male; Middle Aged; Neoplasms; Retrospective Studies; Steroids; T-Lymphocytes; Young Adult | 2013 |
Cancer-free survival of psoriasis patients treated with methotrexate and cyclosporine combination.
Topics: Adult; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Neoplasms; Psoriasis; Surveys and Questionnaires; Turkey | 2014 |
Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients.
Topics: Adult; Cyclosporine; Female; Follow-Up Studies; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Incidence; Liver Failure; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Neoplasms; Proportional Hazards Models; Risk Factors; Sex Factors; Tacrolimus; Treatment Outcome | 2013 |
Epidemiology of post-transplant malignancy in Asian renal transplant recipients: a population-based study.
Topics: Adult; Age Factors; Aged; Asian People; Cyclosporine; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Neoplasms; Risk Factors; Tacrolimus; Taiwan; Time Factors | 2014 |
The case of the toxic transplant tremors.
Topics: Cyclosporine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Neoplasms; Tremor | 2013 |
Cancer risk of immunosuppressants in manufacturing.
Topics: Animals; Cyclosporine; Dose-Response Relationship, Drug; Humans; Immunosuppressive Agents; Inhalation Exposure; Neoplasms; Occupational Exposure | 2014 |
[Lacidipine efficacy and safety for high blood pressure treatment in pediatric oncohematology].
Topics: Adolescent; Antihypertensive Agents; Child; Child, Preschool; Cyclosporine; Dihydropyridines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glomerular Filtration Rate; Glucocorticoids; Humans; Hypertension; Immunosuppressive Agents; Infant; Male; Neoplasms; Retrospective Studies | 2014 |
Consensus on the use of cyclosporine in dermatological practice. Italian Consensus Conference.
Topics: Adult; Child; Cyclosporine; Dermatitis, Atopic; Disease Susceptibility; Drug Administration Schedule; Drug Interactions; Female; Food-Drug Interactions; Humans; Hypertension; Immunosuppressive Agents; Infections; Kidney Diseases; Neoplasms; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications; Psoriasis; Quality of Life; Skin Diseases | 2014 |
The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Asian People; Cohort Studies; Cyclosporine; Etanercept; Female; Humans; Hydroxychloroquine; Immunoglobulin G; Incidence; Insurance; Male; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasms; Outcome Assessment, Health Care; Proportional Hazards Models; Receptors, Tumor Necrosis Factor; Risk Factors; Taiwan; Tumor Necrosis Factor-alpha | 2014 |
Post-transplant malignant neoplasia associated with cyclosporine-based immunotherapy: prevalence, risk factors and survival in feline renal transplant recipients.
Topics: Animals; Case-Control Studies; Cat Diseases; Cats; Cyclosporine; Female; Immunosuppressive Agents; Kidney Transplantation; Male; Neoplasms; Odds Ratio; Retrospective Studies; Risk Factors; Survival Analysis | 2016 |
Incidence of solid organ cancers after liver transplantation: comparison with regional cancer incidence rates and risk factors.
Topics: Adult; Aged; Calcineurin Inhibitors; Cyclosporine; Female; Humans; Immunosuppressive Agents; Incidence; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Neoplasms; Obesity; Risk Factors; Smoking; Tacrolimus; Transplant Recipients | 2015 |
Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy.
Topics: Adult; Azathioprine; Cyclosporine; Female; Follow-Up Studies; Heart Transplantation; Humans; Immunosuppressive Agents; Male; Melanoma; Middle Aged; Multivariate Analysis; Mycophenolic Acid; Neoplasms; Risk Factors; Skin Neoplasms; Survival Analysis; Tacrolimus | 2015 |
De novo cancer avoidance after renal transplantation: A case-control study on low-dose sirolimus combined with a calcineurin inhibitor.
Topics: Adult; Calcineurin Inhibitors; Case-Control Studies; Cyclosporine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Kidney Transplantation; Male; Middle Aged; Multivariate Analysis; Neoplasms; Postoperative Complications; Proportional Hazards Models; Retrospective Studies; Risk Factors; Sirolimus; Survival Rate; Tacrolimus; Taiwan; Treatment Outcome | 2015 |
Cancer Screening of Renal Transplant Patients Undergoing Long-Term Immunosuppressive Therapy.
Topics: Adult; Breast Neoplasms; Carcinoma; Colonic Neoplasms; Cyclosporine; Early Detection of Cancer; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Neoplasms; Retroperitoneal Neoplasms; Sarcoma, Kaposi; Sirolimus; Steroids; Tacrolimus; Thyroid Neoplasms; Time Factors; Urologic Neoplasms | 2015 |
Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.
Topics: Adalimumab; Biological Products; Biological Therapy; Cardiovascular Diseases; Cyclosporine; Dermatologic Agents; Etanercept; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Neoplasms; Psoriasis; Registries; Ustekinumab | 2015 |
Graft-versus-host disease (GVHD) prophylaxis by using methotrexate decreases pre-engraftment syndrome and severe acute GVHD, and accelerates engraftment after cord blood transplantation.
Topics: Adolescent; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclosporine; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Incidence; Infant; Infant, Newborn; Male; Methotrexate; Neoplasms; Neutrophils; Retrospective Studies; Tacrolimus; Time Factors; Transplantation Conditioning; Treatment Outcome | 2016 |
[Applied pharmacogenetic].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Azathioprine; Cyclosporine; Everolimus; Genotype; Humans; Immunosuppressive Agents; IMP Dehydrogenase; Mycophenolic Acid; Neoplasms; Nephrology; Pharmacogenetics; Polymorphism, Genetic; Tacrolimus; Treatment Outcome | 2016 |
British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016.
Topics: Adult; Alcohol Drinking; Biological Products; Bone Marrow Diseases; Checklist; Chemical and Drug Induced Liver Injury; Chickenpox; Child; Counseling; Cyclosporine; Dermatologic Agents; Drug Administration Routes; Drug Administration Schedule; Drug Approval; Drug Interactions; Drug Monitoring; Drug Overdose; Evidence-Based Medicine; Female; Hepatitis, Viral, Human; HIV Infections; Humans; Intraoperative Complications; Kidney Diseases; Lung Diseases; Methotrexate; Nausea; Neoplasms; Off-Label Use; Patient Education as Topic; Patient Safety; Pregnancy; Pregnancy Complications; Retinoids; Skin Diseases; Tuberculosis; Ultraviolet Rays; Vaccination | 2016 |
Pediatric Patients With Solid or Hematological Tumor Disease: Vancomycin Population Pharmacokinetics and Dosage Optimization.
Topics: Anti-Bacterial Agents; Child; Cyclosporine; Drug Dosage Calculations; Drug Monitoring; Drug Therapy, Combination; Febrile Neutropenia; Female; Hematologic Neoplasms; Humans; Infusions, Intravenous; Male; Models, Biological; Neoplasms; Retrospective Studies; Vancomycin | 2016 |
Clinical and radiological features of brain neurotoxicity caused by antitumor and immunosuppressant treatments.
Topics: Adult; Aged; Antineoplastic Agents; Asparaginase; Brain; Cerebral Veins; Child; Cyclosporine; Diagnosis, Differential; Female; Graft Rejection; Humans; Immunosuppressive Agents; Liver Transplantation; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Paraneoplastic Syndromes, Nervous System; Radiotherapy; Risk Factors; Venous Thrombosis | 2008 |
Incidence and risk factors for development of malignant neoplasia after feline renal transplantation and cyclosporine-based immunosuppression.
Topics: Animals; Case-Control Studies; Cat Diseases; Cats; Cyclosporine; Female; Humans; Immunosuppressive Agents; Incidence; Kidney Transplantation; Logistic Models; Male; Neoplasms; Risk Factors; Survival Analysis; Time Factors; Wisconsin | 2009 |
Evaluation of (64)Cu(DO3A-xy-TPEP) as a potential PET radiotracer for monitoring tumor multidrug resistance.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; Cell Line, Tumor; Copper; Cyclosporine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Space; Liver; Metabolic Clearance Rate; Mice; Multidrug Resistance-Associated Proteins; Neoplasms; Organometallic Compounds; Organophosphorus Compounds; Positron-Emission Tomography; Radioactive Tracers; Tissue Distribution | 2009 |
Prolonged fever, hepatosplenomegaly, and pancytopenia in a 46-year-old woman.
Topics: Adrenal Cortex Hormones; Amphotericin B; Animals; Communicable Diseases; Cyclosporine; Diagnosis, Differential; Female; Fever; Hepatomegaly; Humans; Immunosuppressive Agents; Leishmania infantum; Leishmaniasis, Visceral; Liposomes; Lymphohistiocytosis, Hemophagocytic; Macrophages; Middle Aged; Neoplasms; Opportunistic Infections; Pancytopenia; Polymerase Chain Reaction; Splenomegaly | 2009 |
Protocol conversion from a calcineurin inhibitor based therapy to sirolimus.
Topics: Biopsy; Calcineurin Inhibitors; Cyclosporine; Follow-Up Studies; Glomerular Filtration Rate; Humans; Immunosuppressive Agents; Kidney Transplantation; Neoplasms; Randomized Controlled Trials as Topic; Safety; Sirolimus; Treatment Failure; Treatment Outcome | 2009 |
The supernatant of apoptotic cells causes transcriptional activation of hypoxia-inducible factor-1alpha in macrophages via sphingosine-1-phosphate and transforming growth factor-beta.
Topics: Animals; Apoptosis; Calcineurin; Calcineurin Inhibitors; Culture Media, Conditioned; Cyclosporine; Gene Expression Regulation; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunosuppressive Agents; Jurkat Cells; Lysophospholipids; Macrophages; Mice; Mice, Knockout; Neoplasms; NFATC Transcription Factors; Platelet Endothelial Cell Adhesion Molecule-1; RNA, Messenger; Sphingosine; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A | 2009 |
Post-transplantation malignancy: a cell autonomous mechanism with implications for therapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Cyclosporine; Humans; Immunosuppressive Agents; Kidney Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, SCID; Neoplasm Invasiveness; Neoplasms; Organ Transplantation; Phenotype; Sirolimus; Tacrolimus | 2009 |
The effects of drug transporter inhibitors on the pharmacokinetics and tissue distribution of methotrexate in normal and tumor-bearing mice: a microdialysis study.
Topics: Animals; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cyclosporine; Drug Delivery Systems; Drug Interactions; Female; Humans; Methotrexate; Mice; Mice, Nude; Microdialysis; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasms; Probenecid; Tissue Distribution; Xenograft Model Antitumor Assays | 2010 |
Malignancy after heart transplantation.
Topics: Adolescent; Adult; Aged; Child; Cyclosporine; Heart Transplantation; Humans; Incidence; Lymphoproliferative Disorders; Middle Aged; Neoplasms; Risk Factors; Skin Neoplasms | 2009 |
[Solid malignancy in patients who received cyclosporine for fibrosing interstitial pneumonia].
Topics: Aged; Calcineurin Inhibitors; Cohort Studies; Cyclosporine; Drug Therapy, Combination; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasms; Prospective Studies; Steroids | 2010 |
Immunosuppression, cancer, and the long-term outcomes after liver transplantation: can we do better?
Topics: Cyclosporine; Graft Rejection; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Liver Transplantation; Monitoring, Immunologic; Neoplasms; Risk Factors | 2010 |
Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age.
Topics: Adolescent; Adult; Age Factors; Aged; Cyclosporine; Female; Graft Rejection; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Incidence; Liver Transplantation; Male; Middle Aged; Monitoring, Immunologic; Monitoring, Physiologic; Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Tacrolimus; Young Adult | 2010 |
Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05%.
Topics: Administration, Topical; Adolescent; Adult; Aged; Bone Marrow Transplantation; Child; Child, Preschool; Cyclosporine; Dry Eye Syndromes; Female; Fluorescein; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lissamine Green Dyes; Male; Middle Aged; Neoplasms; Retrospective Studies; Surveys and Questionnaires; Tears; Treatment Outcome | 2010 |
Effects of the new immunosuppressive agents on the occurrence of malignancies after renal transplantation.
Topics: Adult; Azathioprine; Cyclosporine; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Neoplasms; Tacrolimus | 2010 |
CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.
Topics: Animals; Apoptosis; CD4-Positive T-Lymphocytes; Cell Proliferation; Cellular Senescence; Chemokines; Cyclosporine; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Gene Silencing; Immunosuppressive Agents; Leukemia, Experimental; Mice; Mice, Transgenic; Neoplasms; Neovascularization, Pathologic; Oncogenes; Proto-Oncogene Proteins c-myc; Remission Induction; Thrombospondin 1; Tumor Microenvironment | 2010 |
Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal.
Topics: Adolescent; Adult; Azathioprine; Calcineurin Inhibitors; Cyclosporine; Drug Therapy, Combination; Everolimus; Female; Germany; Heart Transplantation; Humans; Immunosuppressive Agents; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Mycophenolic Acid; Neoplasms; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Sirolimus; Skin Neoplasms; Survival Rate; Time Factors; TOR Serine-Threonine Kinases; Transplantation, Homologous; Treatment Outcome; Young Adult | 2010 |
Cyclosporin A, but not everolimus, inhibits DNA repair mediated by calcineurin: implications for tumorigenesis under immunosuppression.
Topics: Calcineurin; Cell Line, Transformed; Cell Survival; Cyclosporine; DNA Repair; Everolimus; Fibroblasts; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Lymphocytes; Neoplasms; Phosphorylation; Pyrimidine Dimers; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Small Interfering; Sirolimus; Transfection; Ultraviolet Rays | 2011 |
Cyclosporin A.
Topics: Animals; Carcinogens; Cyclosporine; Humans; Immunosuppressive Agents; Neoplasms | 2011 |
Pharmacodynamic monitoring of cyclosporin A reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older.
Topics: Aged; Calcineurin Inhibitors; Cohort Studies; Cyclosporine; Cytokines; Drug Monitoring; Enzyme Inhibitors; Female; Follow-Up Studies; Gene Expression Regulation; Germany; Graft Rejection; Humans; Immunosuppression Therapy; Incidence; Kidney Transplantation; Lymphocytes; Male; Neoplasms; Opportunistic Infections; Prospective Studies; RNA, Messenger | 2011 |
Cancer rates after kidney transplantation.
Topics: Adult; Antibodies, Monoclonal; Basiliximab; Confidence Intervals; Cyclosporine; Denmark; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Mycophenolic Acid; Neoplasms; Prevalence; Recombinant Fusion Proteins; Retrospective Studies; Risk | 2011 |
Management of acute, severe ulcerative colitis.
Topics: Acute Disease; Antibodies, Monoclonal; Colectomy; Colitis, Ulcerative; Cyclosporine; Exsanguination; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Infliximab; Neoplasms; Severity of Illness Index | 2012 |
Long-term results of conversion from calcineurin inhibitors to sirolimus in 150 maintenance kidney transplant patients.
Topics: Adult; Aged; Calcineurin Inhibitors; Cyclosporine; Enzyme Inhibitors; Female; Follow-Up Studies; Glomerular Filtration Rate; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Neoplasms; Opportunistic Infections; Postoperative Complications; Proteinuria; Retrospective Studies; Sirolimus; Tacrolimus | 2012 |
Cyclosporine induces up-regulation of immunoglobulin-like transcripts 3 and 4 expression on and activity of NKL cells.
Topics: Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Cyclosporine; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Flow Cytometry; HLA-G Antigens; Humans; Immunosuppressive Agents; Killer Cells, Natural; Membrane Glycoproteins; Neoplasms; Real-Time Polymerase Chain Reaction; Receptors, Cell Surface; Receptors, Immunologic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Transcription, Genetic; Up-Regulation | 2012 |
Cytotoxic effect of cyclosporin A alone and in combination with 2-chlorodeoxyadenosine against P388 murine leukemia in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclosporine; Drug Synergism; Immunosuppressive Agents; Male; Mice; Neoplasm Transplantation; Neoplasms; Purines; Time Factors; Tumor Cells, Cultured | 2002 |
Care of the kidney transplant recipient. Vigilant monitoring creates the best outcome.
Topics: Cardiovascular Diseases; Cyclosporine; Cytomegalovirus Infections; Glucocorticoids; Humans; Immunosuppressive Agents; Kidney Transplantation; Metabolic Diseases; Monitoring, Physiologic; Neoplasms; Risk Assessment; Sirolimus; Tacrolimus; Transplantation, Homologous | 2002 |
Malignancy after renal transplantation: incidence and role of type of immunosuppression.
Topics: Adolescent; Adult; Aged; Cyclosporine; Female; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Incidence; Kidney Transplantation; Male; Middle Aged; Neoplasms; Retrospective Studies; Risk Factors; Survival Analysis | 2002 |
DNA repair in mononuclear cells: role of serine/threonine phosphatases.
Topics: Calcineurin; Calcineurin Inhibitors; Cyclosporine; DNA Repair; Enzyme Inhibitors; Humans; Immunosuppressive Agents; In Vitro Techniques; Kidney Transplantation; Leukocytes, Mononuclear; Marine Toxins; Neoplasms; Oxazoles; Phosphates; Phosphoprotein Phosphatases; Signal Transduction; Tacrolimus; Ultraviolet Rays | 2002 |
EVE/cyclosporin (etoposide, vincristine, epirubicin with high-dose cyclosporin)-chemotherapy selected for multidrug resistance modulation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclosporine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Kidney Diseases; Male; Neoplasms; Vincristine | 2002 |
Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen: a single institution experience.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Erythrocyte Transfusion; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Humans; Male; Methotrexate; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Platelet Transfusion; Prospective Studies; Recombinant Proteins; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2003 |
De novo tumors after kidney transplantation: the Budapest experience.
Topics: Azathioprine; Cyclosporine; Female; Humans; Hungary; Immunosuppressive Agents; Kidney Transplantation; Neoplasms; Postoperative Complications; Prednisolone; Retrospective Studies; Risk Factors; Tacrolimus | 2003 |
Analysis of survivors more than 10 years after heart transplantation in the cyclosporine era: Stanford experience.
Topics: Adult; Cohort Studies; Coronary Artery Disease; Cyclosporine; Diabetes Mellitus; Female; Graft Rejection; Heart Transplantation; Humans; Hyperlipidemias; Hypertension; Immunosuppressive Agents; Incidence; Male; Neoplasms; Registries; Renal Insufficiency; Survival Analysis; Survival Rate; Time Factors | 2004 |
Single-center experience with cyclosporine therapy for kidney transplantation: analysis of a twenty-year period in 1200 patients.
Topics: Adult; Cyclosporine; Drug Therapy, Combination; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Middle Aged; Neoplasms; Postoperative Complications; Retrospective Studies; Survival Analysis; Tissue Donors | 2004 |
Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.
Topics: Chemoprevention; Cyclosporine; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Incidence; Kidney Transplantation; Multicenter Studies as Topic; Neoplasms; Neoplasms, Second Primary; Retrospective Studies; Sirolimus; Skin Neoplasms | 2004 |
Molecular effects of cyclosporine and oncogenesis: a new model.
Topics: Animals; Apoptosis; Cyclosporine; DNA Repair; Graft Rejection; Humans; Immunosuppressive Agents; Lymphocyte Activation; Models, Biological; Neoplasms | 2004 |
Feasibility of early tapering of cyclosporine following reduced-intensity stem cell transplantation for advanced hematologic or solid malignancies.
Topics: Adult; Cyclosporine; Graft vs Host Disease; Humans; Immunosuppressive Agents; Middle Aged; Neoplasms; Retrospective Studies; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2005 |
Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients.
Topics: Adolescent; Adult; Aged; Cyclosporine; Female; Humans; Immunosuppressive Agents; Incidence; Kidney Transplantation; Male; Middle Aged; Neoplasms; Risk Factors; Sirolimus; Treatment Outcome | 2005 |
Long-term kinetic of T-lymphocyte subsets in kidney-transplant recipients: influence of anti-T-cell antibodies and association with posttransplant malignancies.
Topics: Adult; CD4 Lymphocyte Count; CD4-CD8 Ratio; Cyclosporine; Female; Humans; Kidney Transplantation; Male; Middle Aged; Neoplasms; T-Lymphocyte Subsets | 2005 |
A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Phytogenic; Area Under Curve; Capsules; Central Nervous System Diseases; Chemistry, Pharmaceutical; Cyclosporine; Female; Gastrointestinal Diseases; Half-Life; Hematologic Diseases; Humans; Immunosuppressive Agents; Injections, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Polymers | 2007 |
[Cancer and immunosuppression: pro- and antitumoral effects of immunosuppressive drugs].
Topics: Azathioprine; Cyclosporine; DNA Repair; Glucocorticoids; Humans; Immunosuppressive Agents; Mycophenolic Acid; Neoplasms; Tacrolimus; Transplantation | 2005 |
Excess risk of cancer in renal transplant patients.
Topics: Adult; Cyclosporine; Female; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Diseases; Kidney Transplantation; Male; Middle Aged; Neoplasms; Retrospective Studies; Risk; Time Factors | 2006 |
Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies.
Topics: Adult; Aged; Analysis of Variance; Cyclosporine; Drug Monitoring; Female; Gene Expression Regulation; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Infections; Interferon-gamma; Interleukin-2; Kidney Transplantation; Male; Middle Aged; Neoplasms; NFATC Transcription Factors; Postoperative Complications; Recurrence | 2006 |
For organ transplant recipients, cancer threatens long-term survival.
Topics: Angiogenesis Inhibitors; Cyclosporine; Humans; Immunosuppressive Agents; Neoplasms; Organ Transplantation; Sarcoma, Kaposi; Sirolimus; Tacrolimus; United States | 2007 |
Risk factors for malignancy in Japanese renal transplant recipients.
Topics: Adult; Age Factors; Azathioprine; Cyclosporine; Female; Humans; Immunosuppressive Agents; Japan; Kidney Transplantation; Male; Neoplasms; Risk Factors; Survival Rate; Tacrolimus | 2007 |
Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Topics: Azathioprine; Cyclosporine; Enzyme Inhibitors; Heart Transplantation; Humans; Immunosuppressive Agents; Kidney Transplantation; Neoplasms; Postoperative Complications; Protein Kinases; Risk; Risk Factors; Tacrolimus; TOR Serine-Threonine Kinases | 2007 |
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Black or African American; Black People; Cohort Studies; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Organic Anion Transporters; Taxoids; White People; Xenobiotics | 2007 |
Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Child; Cyclosporine; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kinetics; Leukemia; Lymphoma; Male; Middle Aged; Neoplasms; Transplantation, Homologous | 2007 |
Drug-drug interactions with systemic antifungals in clinical practice.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Creatinine; Cyclosporine; Drug Interactions; Female; Fluconazole; France; Furosemide; HIV Infections; Hospitals, University; Humans; Hydrocortisone; Hypokalemia; Intensive Care Units; Itraconazole; Kidney Diseases; Leukemia; Male; Middle Aged; Neoplasms; Retrospective Studies | 2007 |
Inhibition of multidrug resistance by adamantylgb3, a globotriaosylceramide analog.
Topics: Adamantane; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Caco-2 Cells; Calcium Channel Blockers; Cell Membrane; Cell Polarity; Cyclosporine; Dogs; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endocytosis; Enzyme Inhibitors; Fluorescent Dyes; Golgi Apparatus; Humans; Intestinal Mucosa; Neoplasms; Protein Binding; Protein Structure, Secondary; Protein Synthesis Inhibitors; Protein Transport; Rhodamine 123; Shiga Toxins; Time Factors; Trihexosylceramides; Up-Regulation; Verapamil; Vinblastine | 2008 |
Long-term complications of cardiac transplantation.
Topics: Coronary Disease; Cyclosporine; Graft Rejection; Heart Transplantation; Humans; Kidney; Neoplasms; Postoperative Complications; Survival Rate; Time Factors | 1995 |
Pediatric renal transplantation at the University of Minnesota: the cyclosporine years.
Topics: Actuarial Analysis; Child; Child, Preschool; Cyclosporine; Demography; Female; Graft Rejection; Hospitals, University; Humans; Immunosuppression Therapy; Infant; Kidney Transplantation; Kidney Tubular Necrosis, Acute; Male; Minnesota; Neoplasms; Postoperative Complications; Retrospective Studies; Survival Analysis; Survival Rate; Treatment Outcome | 1994 |
Risk of neoplasia in renal transplant patients.
Topics: Adult; Carcinoma, Squamous Cell; Cyclosporine; Data Collection; Databases, Factual; England; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Neoplasms; Retrospective Studies; Risk Factors; Skin Neoplasms; Survival Analysis | 1995 |
Incidence and type of malignancies occurring after renal transplantation in conventionally and in cyclosporine-treated recipients: single-center analysis of a 20-year period in 1600 patients.
Topics: Adult; Cyclosporine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Incidence; Kidney Transplantation; Leukemia; Lymphoma; Male; Melanoma; Neoplasms; Risk Factors; Skin Neoplasms; Time Factors | 1995 |
Heart transplantation is a valid therapeutic option for anthracycline cardiomyopathy.
Topics: Actuarial Analysis; Adult; Azathioprine; Cardiomyopathies; Cyclosporine; Daunorubicin; Doxorubicin; Female; Heart Transplantation; Humans; Immunosuppression Therapy; Male; Neoplasms; Prednisolone; Survival Rate | 1995 |
Incidence and type of malignancies occurring after renal transplantation in conventionally and cyclosporine-treated recipients: analysis of a 20-year period in 1600 patients.
Topics: Adult; Carcinoma; Cyclosporine; Drug Therapy, Combination; Female; Follow-Up Studies; Glioblastoma; Graft Survival; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Incidence; Kidney Transplantation; Male; Neoplasms; Retrospective Studies; Sarcoma, Kaposi; Skin Neoplasms; Survival Rate; Time Factors | 1995 |
Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity.
Topics: Animals; Antibodies, Monoclonal; Blood Vessels; Cyclosporine; Dexamethasone; Diphenhydramine; Female; Guanidines; Hematocrit; Humans; Hydrothorax; Immunosuppressive Agents; Immunotoxins; Lung; Macrophages, Alveolar; Neoplasms; Rats; Rats, Inbred WF; Rats, Nude; Recombinant Fusion Proteins; Transplantation, Heterologous | 1994 |
Malignancy under immunosuppressive therapy including cyclosporine.
Topics: Adult; Azathioprine; Cyclosporine; Female; Follow-Up Studies; Graft Survival; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Methylprednisolone; Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Time Factors | 1994 |
De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients.
Topics: Adult; Cyclosporine; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Survival; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Incidence; Kidney Transplantation; Life Tables; Lymphoma; Male; Middle Aged; Neoplasms; Proportional Hazards Models; Risk Factors; Skin Neoplasms; Time Factors | 1994 |
Enhanced toxicity of dactinomycin and vincristine by cyclosporine given to reverse multidrug resistance.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Dactinomycin; Drug Resistance; Humans; Male; Neoplasms; Vincristine | 1994 |
Cancer development in pediatric primary renal allograft recipients.
Topics: Adolescent; Adult; Age Factors; Child; Cyclosporine; Female; Humans; Immunosuppression Therapy; Kidney Transplantation; Lymphoma; Male; Minnesota; Neoplasms; Skin Neoplasms | 1994 |
Modulation of multidrug resistance: at the threshold.
Topics: Antineoplastic Agents; Cyclosporine; Drug Resistance; Humans; Neoplasms | 1993 |
De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation.
Topics: Australia; Azathioprine; Cadaver; Cyclosporine; Female; Humans; Kidney Transplantation; Morbidity; Neoplasms; New Zealand; Prednisone; Probability; Registries; Risk Factors; Skin Neoplasms; Time Factors; Tissue Donors; Treatment Failure | 1993 |
Malignancies under cyclosporine after kidney transplantation: analysis of a 10-year period.
Topics: Adult; Cyclosporine; Female; Follow-Up Studies; Histocompatibility Testing; Humans; Incidence; Kidney Transplantation; Male; Neoplasms; Registries; Retrospective Studies; Time Factors | 1993 |
Cancers in cyclosporine-treated vs azathioprine-treated patients.
Topics: Adult; Azathioprine; Child; Cyclosporine; Female; Humans; Immunosuppressive Agents; Kidney Neoplasms; Kidney Transplantation; Lip Neoplasms; Lymphoma; Neoplasms; Sarcoma, Kaposi; Skin Neoplasms; Transplantation Immunology; Uterine Cervical Neoplasms; Vulvar Neoplasms | 1996 |
Increasing transplant cancer patient survival by conversion of immunosuppressive agents.
Topics: Adult; Cyclosporine; Female; Follow-Up Studies; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Incidence; Kidney Transplantation; Male; Neoplasms; Survival Rate | 1996 |
Tumors after renal transplantation.
Topics: Adult; Azathioprine; Child; Cyclosporine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Neoplasms; Postoperative Complications; Retrospective Studies; Steroids | 1996 |
Tumors after renal transplantation.
Topics: Adolescent; Adult; Child; Cyclosporine; Female; Follow-Up Studies; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Incidence; Kidney Transplantation; Male; Middle Aged; Neoplasms; Postoperative Complications; Retrospective Studies; Risk Factors; Time Factors | 1996 |
Posttransplant malignancy and newer immunosuppressive protocols after liver transplantation.
Topics: Carcinoma, Hepatocellular; Cyclosporine; Follow-Up Studies; Hepatitis B; Hepatitis C; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Lymphoma; Neoplasms; Postoperative Complications; Retrospective Studies; Tacrolimus; Time Factors | 1996 |
Tumors after transplantation: are there associated factors?
Topics: Cyclosporine; Female; Follow-Up Studies; Graft Rejection; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Neoplasms; Postoperative Complications; Risk Factors; Time Factors | 1996 |
Impairment of DNA repair in the course of long-term hemodialysis and under cyclosporine immunosuppression after renal transplantation.
Topics: Aged; Analysis of Variance; Cells, Cultured; Creatinine; Cyclosporine; DNA Damage; DNA Repair; Female; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Lymphocytes; Male; Middle Aged; Neoplasms; Reference Values; Regression Analysis; Renal Dialysis; Smoking; Thymidine; Ultraviolet Rays | 1996 |
Cancer risk after renal transplantation in Japan.
Topics: Adolescent; Adult; Age Distribution; Carcinoma, Renal Cell; Child; Cyclosporine; Female; Follow-Up Studies; Humans; Immunocompromised Host; Immunosuppressive Agents; Incidence; Japan; Kidney Neoplasms; Kidney Transplantation; Male; Middle Aged; Neoplasms; Postoperative Complications; Risk; Sex Distribution | 1997 |
Study of malignancy among Egyptian kidney transplant recipients.
Topics: Azathioprine; Cyclosporine; Egypt; Female; Graft Survival; Humans; Immunosuppressive Agents; Incidence; Kidney Transplantation; Male; Middle Aged; Neoplasms; Postoperative Complications; Recurrence; Retrospective Studies; Sarcoma, Kaposi; Skin Neoplasms | 1997 |
Pilot study of multiple chemotherapy resistance modulators plus epirubicin in the treatment of resistant malignancies.
Topics: Adjuvants, Pharmaceutic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antifungal Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Antitrichomonal Agents; Cyclosporine; Dipyridamole; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Immunosuppressive Agents; Ketoconazole; Male; Metronidazole; Middle Aged; Neoplasms; Pilot Projects; Tamoxifen; Vasodilator Agents | 1997 |
Risk of cancer with cyclosporine in psoriasis.
Topics: Adult; Age Factors; Clinical Trials as Topic; Cyclosporine; Data Collection; Florida; Humans; Immunosuppressive Agents; Incidence; Michigan; Middle Aged; Neoplasms; Psoriasis; Risk Assessment; Risk Factors; Time Factors | 1997 |
Acute pancreatitis in marrow transplant patients: prevalence at autopsy and risk factor analysis.
Topics: Abdominal Pain; Acute Disease; Adult; Amylases; Bile; Biomarkers; Bone Marrow Transplantation; Cause of Death; Cohort Studies; Cyclosporine; Drug Therapy, Combination; Female; Gallbladder; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Methotrexate; Neoplasms; Pancreatitis; Prednisone; Prevalence; Risk Factors; Transplantation Conditioning; Whole-Body Irradiation | 1997 |
Does the multidrug-resistance modulator cyclosporin A increase the cardiotoxicity of high-dose anthracycline chemotherapy?
Topics: Adolescent; Adult; Aged; Analysis of Variance; Animals; Antibiotics, Antineoplastic; Cyclosporine; Doxorubicin; Drug Resistance, Multiple; Drug Synergism; Epirubicin; Female; Heart; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasms; Ventricular Function, Left | 1997 |
[Critical review of renal transplantation data from the Piedmontese Regional Dialysis and Transplantation Registry].
Topics: Adolescent; Adult; Cardiovascular Diseases; Cause of Death; Child; Child, Preschool; Cyclosporine; Drug Utilization; Female; Humans; Immunosuppressive Agents; Infant; Infections; Italy; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Neoplasms; Registries; Reoperation; Survival Analysis | 1998 |
Higher incidence of malignant neoplasms after heart transplantation for treatment of chronic Chagas' heart disease.
Topics: Adult; Carcinoma, Squamous Cell; Chagas Cardiomyopathy; Chemoprevention; Chronic Disease; Cocarcinogenesis; Cyclosporine; Female; Follow-Up Studies; Heart Failure; Heart Transplantation; Humans; Immunosuppressive Agents; Incidence; Lung Diseases; Lymphoproliferative Disorders; Male; Mutagens; Neoplasms; Neurilemmoma; Nitroimidazoles; Recurrence; Sarcoma, Kaposi; Skin Neoplasms; Survival Rate; Trypanocidal Agents | 1998 |
The role of cyclosporin A on antibody-dependent monocyte-mediated cytotoxicity against human multidrug-resistant cancer cells.
Topics: Antibodies, Monoclonal; Cell Line; Cyclosporine; Cytotoxicity, Immunologic; Drug Resistance, Multiple; Humans; Monocytes; Neoplasms | 1998 |
Long-term outcome with the use of OKT3 induction therapy in heart transplant patients: a single-center experience.
Topics: Azathioprine; Cyclosporine; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Heart Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Muromonab-CD3; Neoplasms; Postoperative Complications; Retrospective Studies; Steroids; Survival Rate; Time Factors; Treatment Outcome | 1998 |
Reduced severity of acute rejection in hepatitis C virus positive renal allograft recipients: are milder immunosuppressive regimens advisable?
Topics: Cyclosporine; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Hepatitis C; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Incidence; Kidney Transplantation; Male; Muromonab-CD3; Neoplasms; Postoperative Complications; Prednisone; Retrospective Studies; Time Factors; Transplantation, Homologous | 1998 |
Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors.
Topics: Adult; Aged; Cyclosporine; Female; Graft Rejection; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Retrospective Studies; Risk Assessment; Survival Analysis | 1998 |
[Long-term follow-up of anatomic heart transplantation. Apropos of 60 patients with a mean follow-up of 36 months].
Topics: Actuarial Analysis; Adult; Aged; Biopsy; Cause of Death; Chronic Disease; Creatinine; Cyclosporine; Death, Sudden, Cardiac; Echocardiography; Female; Follow-Up Studies; Graft Rejection; Heart Transplantation; Humans; Hypertension; Immunosuppressive Agents; Longitudinal Studies; Male; Middle Aged; Mitral Valve Insufficiency; Neoplasms; Pancreatitis; Survival Analysis; Survival Rate; Tricuspid Valve Insufficiency | 1998 |
Effect of two cyclosporin regimens on cancer frequency in kidney-graft recipients.
Topics: Cyclosporine; Drug Administration Schedule; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Neoplasms | 1998 |
No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Comorbidity; Cyclosporine; Female; Humans; Male; Middle Aged; Neoplasms; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome | 1998 |
Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis.
Topics: Adolescent; Adult; Age Factors; Bone Marrow Transplantation; Child; Child, Preschool; Chronic Disease; Cyclosporine; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infant; Male; Methotrexate; Middle Aged; Neoplasms; Retrospective Studies; Risk Factors; Sex Factors; Transplantation, Homologous | 1998 |
Successful conversion from cyclosporine to azathioprine in elective renal transplant recipients.
Topics: Adult; Azathioprine; Cyclosporine; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Incidence; Kidney Transplantation; Male; Middle Aged; Neoplasms; Postoperative Complications; Prednisolone | 1998 |
Malignant neoplasm in kidney transplantation.
Topics: Adolescent; Adult; Azathioprine; CD4-Positive T-Lymphocytes; Cyclosporine; Female; Follow-Up Studies; Herpesvirus 4, Human; Humans; Immunosuppression Therapy; Kidney Transplantation; Male; Middle Aged; Neoplasms; Retrospective Studies; Time Factors | 1998 |
A transformed view of cyclosporine.
Topics: Animals; Carcinogens; Cyclosporine; Cytokines; Humans; Immunosuppressive Agents; Mice; Neoplasms; Transforming Growth Factor beta; Tumor Cells, Cultured | 1999 |
A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier.
Topics: Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Brain Chemistry; Calcium Channel Blockers; Carcinoma, Small Cell; Cyclosporine; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms; Rats; Rats, Nude; Recombinant Fusion Proteins; Tissue Distribution; Tumor Cells, Cultured; Verapamil | 1999 |
The incidence of malignancy in heart transplant recipients.
Topics: Adult; Aged; Azathioprine; Cyclosporine; Female; Heart Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Neoplasms; Poland; Prospective Studies; Retrospective Studies | 1998 |
Does cyclosporin A cause cancer?
Topics: Animals; Anticarcinogenic Agents; Carcinogens; Cyclosporine; Humans; Immunosuppressive Agents; Mice; Mice, SCID; Neoplasms; Risk; Risk Factors | 1999 |
Risk of malignancy associated with cyclosporin use in psoriasis.
Topics: Cyclosporine; Dermatologic Agents; Humans; Neoplasms; Psoriasis; Risk Factors | 1999 |
Cyclosporin A inhibits Ca2+-mediated upregulation of the DNA repair enzyme DNA polymerase beta in human peripheral blood mononuclear cells.
Topics: Animals; Base Sequence; Calcineurin; Calcium; Cyclosporine; DNA Polymerase beta; DNA Primers; DNA Repair; Humans; Immunosuppressive Agents; In Vitro Techniques; Ionomycin; Ionophores; Leukocytes, Mononuclear; Neoplasms; RNA, Messenger; Tacrolimus; Tetradecanoylphorbol Acetate; Up-Regulation | 1999 |
Impact of acute rejection therapy on infections and malignancies in renal transplant recipients.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Communicable Diseases; Cyclosporine; Female; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Muromonab-CD3; Neoplasms; Postoperative Complications; Retrospective Studies; Risk; Risk Factors; Survival Analysis; Time Factors | 1999 |
Effect of immunosuppressive therapy on DNA repair and cancer incidence in renal transplant recipients.
Topics: Adult; Aged; Azathioprine; Cyclosporine; DNA Repair; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Lymphocytes; Male; Middle Aged; Neoplasms; Postoperative Complications; Prednisone; Reference Values | 2000 |
From the Food and Drug Administration.
Topics: Administration, Oral; Antiviral Agents; Cyclosporine; Drug and Narcotic Control; Drug Labeling; Fluoxetine; Guanidines; Health Education; Humans; Immunosuppressive Agents; Internet; Neoplasms; Premenstrual Syndrome; Pyrans; Selective Serotonin Reuptake Inhibitors; Sialic Acids; United States; United States Food and Drug Administration; Zanamivir | 2000 |
Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cyclosporine; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel | 2000 |
Existence of serum p53 antibodies in cyclosporine A-treated transplant patients: possible detection of p53 protein over-expression.
Topics: Adolescent; Adult; Aged; Autoantibodies; Biomarkers; Child; Cyclosporine; Female; Gene Expression Regulation; Genes, p53; Humans; Kidney Transplantation; Male; Middle Aged; Neoplasms; Prednisone; Reference Values; Tacrolimus; Tumor Suppressor Protein p53 | 2000 |
Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cyclosporine; Drug Synergism; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel | 2000 |
Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Cyclosporine; DNA Repair; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Humans; Immunosuppressive Agents; In Vitro Techniques; Incidence; Kidney Failure, Chronic; Kidney Transplantation; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasms; Prednisolone | 2001 |
Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel.
Topics: Absorption; Administration, Oral; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Cyclosporine; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Neoplasms; Paclitaxel | 2001 |
One thousand renal transplants at Belfast City Hospital: post-graft neoplasia 1968-1999, comparing azathioprine only with cyclosporin-based regimes in a single centre.
Topics: Azathioprine; Cyclosporine; Female; Hospitals, Urban; Humans; Immunosuppressive Agents; Ireland; Kidney Transplantation; Male; Neoplasms; Recurrence; Risk Factors; Time Factors | 2000 |
Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Area Under Curve; Cyclosporine; Docetaxel; Drug Interactions; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2001 |
[mTOR and FTY 720 inhibitors].
Topics: Cyclosporine; Drug Interactions; Drug Therapy, Combination; Everolimus; Fingolimod Hydrochloride; Hyperlipidemias; Immunosuppressive Agents; Kidney; Neoplasms; Propylene Glycols; Sirolimus; Sphingosine | 2001 |
Incidence of de novo malignancies in renal transplant patients after anti-T-lymphocytic therapy.
Topics: Adult; Antilymphocyte Serum; Cyclosporine; Humans; Immunosuppressive Agents; Incidence; Kidney Transplantation; Middle Aged; Muromonab-CD3; Neoplasms; Prednisolone; Retrospective Studies | 2001 |
[Analysis of 2200 kidney transplantations].
Topics: Adolescent; Adult; Aged; Child; Cyclosporine; Female; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Liver; Male; Middle Aged; Neoplasms; Survival Rate; Time Factors | 2001 |
Validation: state of the art United States National Toxicology Program & Fischer 344 rat cyclosporine--a study.
Topics: Animals; Cyclosporine; Immune System Diseases; Male; Neoplasms; Rats; Rats, Inbred F344; Toxicology; United States | 1992 |
Allogeneic bone marrow transplantation: the Huddinge experience.
Topics: Adult; Anemia; Bone Marrow Transplantation; Candidiasis; Child; Cyclosporine; Cytomegalovirus Infections; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Incidence; Leukemia; Male; Methotrexate; Neoplasms; Retrospective Studies; Risk Factors; Sweden; Transplantation, Homologous | 1992 |
Evaluation of a method for detection of cells with reduced drug retention in solid tumours.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Breast Neoplasms; Cell Survival; Chromatography, High Pressure Liquid; Culture Media; Cyclosporine; Daunorubicin; Drug Resistance; Female; Flow Cytometry; Friend murine leukemia virus; Humans; Hydrogen-Ion Concentration; Leukemia, Erythroblastic, Acute; Membrane Glycoproteins; Mice; Neoplasm Proteins; Neoplasms; Nephelometry and Turbidimetry; Reference Standards; Reproducibility of Results; Treatment Outcome; Tumor Cells, Cultured; Verapamil | 1992 |
Increased risk of malignant tumors in renal transplant recipients receiving cyclosporine.
Topics: Adult; Azathioprine; Cyclosporine; Female; Humans; Immunosuppression Therapy; Kidney Transplantation; Male; Neoplasms; Prednisone; Retrospective Studies; Risk Factors; Transplantation, Homologous | 1992 |
A statistical study of cancer incidence in renal transplant patients.
Topics: Adolescent; Adult; Azathioprine; Child; Cyclosporine; Female; Humans; Immunosuppression Therapy; Kidney Transplantation; Male; Middle Aged; Neoplasms; Risk Factors | 1992 |
Cancer after transplantation in Catalonia.
Topics: Adult; Azathioprine; Cadaver; Cyclosporine; Female; Humans; Immunosuppression Therapy; Kidney Transplantation; Male; Neoplasms; Prednisone; Retrospective Studies; Skin Neoplasms; Spain; Transplantation, Homologous | 1992 |
Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Cyclosporine; Drug Therapy, Combination; Female; Graft vs Host Disease; HLA Antigens; Humans; Infant; Male; Methotrexate; Middle Aged; Neoplasms; Survival Rate | 1992 |
Pediatric cancer forum examines chemotherapy variables.
Topics: Antineoplastic Agents; Child; Cyclosporine; Humans; Neoplasms; Neuroblastoma | 1991 |
Recent contributions to transplantation at the University of Cincinnati.
Topics: Actuarial Analysis; Adult; Cadaver; Cause of Death; Cyclosporine; Female; Follow-Up Studies; Graft Survival; Heart Transplantation; Histocompatibility Testing; Humans; Immunosuppression Therapy; Kidney Transplantation; Liver Transplantation; Male; Middle Aged; Neoplasms; Ohio; Organ Transplantation; Pancreas Transplantation; Postoperative Complications; Prednisone; Survival Rate | 1991 |